0001628280-22-027931.txt : 20221103 0001628280-22-027931.hdr.sgml : 20221103 20221103060912 ACCESSION NUMBER: 0001628280-22-027931 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 221355999 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 10-Q 1 auph-20220930.htm 10-Q auph-20220930
false2022Q3000160062012-3100016006202022-01-012022-09-3000016006202022-11-02xbrli:shares00016006202022-09-30iso4217:USD00016006202021-12-31iso4217:USDxbrli:shares0001600620us-gaap:ProductMember2022-07-012022-09-300001600620us-gaap:ProductMember2021-07-012021-09-300001600620us-gaap:ProductMember2022-01-012022-09-300001600620us-gaap:ProductMember2021-01-012021-09-300001600620us-gaap:LicenseMember2022-07-012022-09-300001600620us-gaap:LicenseMember2021-07-012021-09-300001600620us-gaap:LicenseMember2022-01-012022-09-300001600620us-gaap:LicenseMember2021-01-012021-09-3000016006202022-07-012022-09-3000016006202021-07-012021-09-3000016006202021-01-012021-09-300001600620us-gaap:CommonStockMember2022-06-300001600620us-gaap:AdditionalPaidInCapitalMember2022-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001600620us-gaap:RetainedEarningsMember2022-06-3000016006202022-06-300001600620us-gaap:CommonStockMember2022-07-012022-09-300001600620us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001600620us-gaap:RetainedEarningsMember2022-07-012022-09-300001600620us-gaap:CommonStockMember2022-09-300001600620us-gaap:AdditionalPaidInCapitalMember2022-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001600620us-gaap:RetainedEarningsMember2022-09-300001600620us-gaap:CommonStockMember2021-06-300001600620us-gaap:AdditionalPaidInCapitalMember2021-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001600620us-gaap:RetainedEarningsMember2021-06-3000016006202021-06-300001600620us-gaap:CommonStockMember2021-07-012021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001600620us-gaap:RetainedEarningsMember2021-07-012021-09-300001600620us-gaap:CommonStockMember2021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001600620us-gaap:RetainedEarningsMember2021-09-3000016006202021-09-300001600620us-gaap:CommonStockMember2021-12-310001600620us-gaap:AdditionalPaidInCapitalMember2021-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001600620us-gaap:RetainedEarningsMember2021-12-310001600620us-gaap:CommonStockMember2022-01-012022-09-300001600620us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001600620us-gaap:RetainedEarningsMember2022-01-012022-09-300001600620us-gaap:CommonStockMember2020-12-310001600620us-gaap:AdditionalPaidInCapitalMember2020-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001600620us-gaap:RetainedEarningsMember2020-12-3100016006202020-12-310001600620us-gaap:CommonStockMember2021-01-012021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001600620us-gaap:RetainedEarningsMember2021-01-012021-09-30auph:segment0001600620us-gaap:CustomerConcentrationRiskMemberauph:SpecialtyPharmacyOneMemberus-gaap:SalesRevenueNetMembercountry:US2022-07-012022-09-30xbrli:pure0001600620us-gaap:CustomerConcentrationRiskMemberauph:SpecialtyPharmacyOneMemberus-gaap:SalesRevenueNetMembercountry:US2022-01-012022-09-300001600620us-gaap:CustomerConcentrationRiskMemberauph:SpecialtyPharmacyOneMemberauph:OutsideUnitedStatesMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001600620us-gaap:CustomerConcentrationRiskMemberauph:SpecialtyPharmacyOneMemberauph:OutsideUnitedStatesMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001600620auph:MilestoneAchievementMember2022-01-012022-09-300001600620auph:OtuskaPharmaceuticalCoLtdMember2022-09-300001600620srt:MinimumMember2022-01-012022-09-300001600620srt:MaximumMember2022-01-012022-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2022-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel2Member2022-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel3Member2022-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2022-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:USAgencySecurityMember2022-09-300001600620us-gaap:FairValueInputsLevel2Memberauph:USAgencySecurityMember2022-09-300001600620us-gaap:FairValueInputsLevel3Memberauph:USAgencySecurityMember2022-09-300001600620auph:USAgencySecurityMember2022-09-300001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001600620us-gaap:CorporateBondSecuritiesMember2022-09-300001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2022-09-300001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2022-09-300001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2022-09-300001600620us-gaap:CommercialPaperMember2022-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2022-09-300001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2022-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2022-09-300001600620us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001600620us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2022-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:YankeeBondMember2022-09-300001600620us-gaap:FairValueInputsLevel2Memberauph:YankeeBondMember2022-09-300001600620us-gaap:FairValueInputsLevel3Memberauph:YankeeBondMember2022-09-300001600620auph:YankeeBondMember2022-09-300001600620us-gaap:FairValueInputsLevel1Member2022-09-300001600620us-gaap:FairValueInputsLevel2Member2022-09-300001600620us-gaap:FairValueInputsLevel3Member2022-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2021-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel2Member2021-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMemberus-gaap:FairValueInputsLevel3Member2021-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2021-12-310001600620us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2021-12-310001600620us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2021-12-310001600620us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2021-12-310001600620us-gaap:CertificatesOfDepositMember2021-12-310001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001600620us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001600620us-gaap:CorporateBondSecuritiesMember2021-12-310001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2021-12-310001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2021-12-310001600620us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2021-12-310001600620us-gaap:CommercialPaperMember2021-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2021-12-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001600620us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2021-12-310001600620us-gaap:FairValueInputsLevel1Member2021-12-310001600620us-gaap:FairValueInputsLevel2Member2021-12-310001600620us-gaap:FairValueInputsLevel3Member2021-12-310001600620us-gaap:FairValueInputsLevel1Member2022-01-012022-09-300001600620us-gaap:FairValueInputsLevel2Member2022-01-012022-09-300001600620us-gaap:FairValueInputsLevel2Member2021-01-012021-12-310001600620us-gaap:FairValueInputsLevel1Member2021-01-012021-12-310001600620us-gaap:CertificatesOfDepositMember2022-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2022-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2021-12-310001600620us-gaap:PatentsMember2022-09-300001600620us-gaap:IntellectualPropertyMember2022-09-300001600620us-gaap:ComputerSoftwareIntangibleAssetMember2022-09-300001600620us-gaap:PatentsMember2021-12-310001600620us-gaap:IntellectualPropertyMember2021-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2021-12-310001600620us-gaap:ConstructionInProgressMember2022-09-300001600620us-gaap:ConstructionInProgressMember2021-12-310001600620us-gaap:LeaseholdImprovementsMember2022-09-300001600620us-gaap:LeaseholdImprovementsMember2021-12-310001600620us-gaap:OfficeEquipmentMember2022-09-300001600620us-gaap:OfficeEquipmentMember2021-12-310001600620us-gaap:FurnitureAndFixturesMember2022-09-300001600620us-gaap:FurnitureAndFixturesMember2021-12-310001600620us-gaap:ComputerEquipmentMember2022-09-300001600620us-gaap:ComputerEquipmentMember2021-12-310001600620auph:VictoriaBritishColumbiaMember2020-12-310001600620auph:VictoriaBritishColumbiaMember2022-08-032022-08-030001600620auph:RockvilleMarylandMember2020-03-31utr:sqftauph:extension_option0001600620auph:RockvilleMarylandMember2020-03-012020-03-310001600620auph:RockvilleMarylandMember2022-09-300001600620auph:RockvilleMarylandMember2021-12-310001600620auph:RockvilleMarylandMember2021-12-312021-12-310001600620auph:RockvilleMarylandMember2020-03-1200016006202021-01-012021-01-31iso4217:CHF00016006202021-02-012021-02-280001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2020-12-172020-12-170001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2020-12-170001600620auph:OtuskaPharmaceuticalCoLtdMembersrt:MinimumMemberus-gaap:LicenseAgreementTermsMember2020-12-170001600620auph:OtuskaPharmaceuticalCoLtdMembersrt:MaximumMemberus-gaap:LicenseAgreementTermsMember2020-12-170001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:LicenseAgreementTermsMember2022-09-150001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMemberus-gaap:LicenseAgreementTermsMember2022-07-012022-09-300001600620auph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMemberus-gaap:LicenseAgreementTermsMember2022-01-012022-09-300001600620auph:RiptideBioscienceIncMemberus-gaap:LicenseAgreementTermsMember2021-08-172021-08-170001600620auph:RiptideBioscienceIncMemberus-gaap:LicenseAgreementTermsMember2022-01-012022-03-310001600620us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001600620us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001600620us-gaap:PerformanceSharesMember2022-01-012022-09-300001600620us-gaap:PerformanceSharesMember2021-01-012021-09-300001600620us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001600620us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001600620us-gaap:WarrantMember2022-01-012022-09-300001600620us-gaap:WarrantMember2021-01-012021-09-300001600620auph:AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap:EmployeeStockMember2021-06-300001600620us-gaap:EmployeeStockMember2021-01-012021-12-31auph:purchase_period0001600620us-gaap:EmployeeStockMember2022-04-012022-06-300001600620us-gaap:EmployeeStockMember2022-01-012022-09-300001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2020-10-232020-10-230001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2021-03-182021-03-180001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2021-08-062021-08-060001600620us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2021-12-310001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2022-01-012022-09-300001600620srt:OfficerMemberauph:PerformanceShareSandRestrictedStockUnitsRSUsMember2022-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001600620us-gaap:InventoriesMember2022-07-012022-09-300001600620us-gaap:InventoriesMember2021-07-012021-09-300001600620us-gaap:InventoriesMember2022-01-012022-09-300001600620us-gaap:InventoriesMember2021-01-012021-09-300001600620auph:ILJINMembersrt:AffiliatedEntityMemberauph:MilestonePaymentMember2021-01-012021-12-310001600620auph:ILJINMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310001600620auph:ILJINMemberus-gaap:OtherCurrentLiabilitiesMember2022-09-300001600620auph:NewEmployeesMember2022-09-302022-09-30auph:employee0001600620auph:NewEmployeesMemberauph:ShareBasedPaymentArrangementInducementOptionMember2022-09-302022-09-300001600620auph:NewEmployeesMemberus-gaap:RestrictedStockUnitsRSUMember2022-09-302022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
#1203-4464 Markham Street
Victoria, British Columbia V8Z 7X8
98-1231763
(Address of principal executive offices)(I.R.S. Employer
Identification Number)
(250) 744-2487
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of November 2, 2022, the registrant had 142,109,703 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30, 2022December 31, 2021
(unaudited)
ASSETS
Current assets
Cash, cash equivalents and restricted cash$86,052 $231,900 
Short-term investments290,592 234,178 
Accounts receivable, net41,771 15,414 
Inventories, net25,320 19,326 
Prepaid expenses12,159 11,710 
Other current assets3,808 796 
Total current assets459,702 513,324 
Non-current assets
Other non-current assets13,049 11,838 
Property and equipment, net3,758 4,418 
Acquired intellectual property and other intangible assets, net6,839 8,404 
Right-of-use assets, net4,945 5,383 
Total assets488,293 543,367 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities40,123 34,947 
Other current liabilities724 4,640 
Operating lease liabilities918 1,059 
Total current liabilities41,765 40,646 
Non-current liabilities
Deferred compensation and other non-current liabilities15,833 15,950 
Operating lease liabilities7,270 7,680 
Total liabilities64,868 64,276 
Commitments and contingencies (Note 17)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
1,184,020 1,177,051 
Additional paid-in capital79,188 59,014 
Accumulated other comprehensive loss(1,527)(852)
Accumulated deficit(838,256)(756,122)
Total shareholders' equity423,425 479,091 
Total liabilities and shareholders’ equity$488,293 $543,367 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
Three months endedNine months ended
September 30,September 30,
2022202120222021
(unaudited)
Revenue
Product revenue, net$25,502 $14,638 $75,142 $22,113 
License and collaboration revenue30,277 29 30,453 88 
Total revenue, net55,779 14,667 105,595 22,201 
Operating expenses
Cost of sales2,447 254 4,302 610 
Selling, general and administrative52,169 44,645 148,898 128,772 
Research and development10,973 20,066 35,118 39,990 
Other (income) expense, net(311)55 647 859 
Total cost of sales and operating expenses65,278 65,020 188,965 170,231 
Loss from operations(9,499)(50,353)(83,370)(148,030)
Interest income1,464 106 2,209 420 
Net loss before income taxes(8,035)(50,247)(81,161)(147,610)
Income tax expense954 8 973 34 
Net loss(8,989)(50,255)(82,134)(147,644)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities, net of tax of nil
326 (2)(675)11 
Comprehensive loss$(8,663)$(50,257)$(82,809)$(147,633)
Basic and diluted loss per share$(0.06)$(0.39)$(0.58)$(1.15)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share141,856 128,443 141,831 128,084 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Three Months Ended September 30, 2022SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2022141,892 $1,180,884 $74,004 $(1,853)$(829,267)$423,768 
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units218 3,136 (3,136)— — — 
Share-based compensation— — 8,320 — — 8,320 
Unrealized gain on available-for-sale securities, net— — — 326 — 326 
Net loss— — — — (8,989)(8,989)
Balance at September 30, 2022142,110 $1,184,020 $79,188 $(1,527)$(838,256)$423,425 
Common Shares
Three Months Ended September 30, 2021SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2021128,396 954,572 51,022 (792)(672,545)332,257 
Shares issued on exercise of stock options1,172 12,579 (3,505)— — 9,074 
Exercise of warrants2 8 (2)— — 6 
Shared-based compensation— — 7,092 — — 7,092 
Unrealized loss on available-for-sale securities, net— — — (2)— (2)
Net loss— — — — (50,255)(50,255)
Balance at September 30, 2021129,570 $967,159 $54,607 $(794)$(722,800)$298,172 
Common Shares
Nine Months Ended September 30, 2022SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2021141,600 $1,177,051 $59,014 $(852)$(756,122)$479,091 
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units383 5,064 (4,542)— — 522 
Issuance of common shares in conjunction with ESPP program127 1,905 (682)— — 1,223 
Share-based compensation— — 25,398 — — 25,398 
Unrealized loss on available-for-sale securities, net— — — (675)— (675)
Net loss— — — — (82,134)(82,134)
Balance at September 30, 2022142,110 $1,184,020 $79,188 $(1,527)$(838,256)$423,425 
Common Shares
Nine Months Ended September 30, 2021SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2020126,725 $944,328 $39,383 $(805)$(575,156)$407,750 
Shares issued on exercise of stock options2,324 22,097 (6,745)— — 15,352 
Exercise of warrants521 734 (697)— — 37 
Shared-based compensation— — 22,666 — — 22,666 
Unrealized gain on available-for-sale securities, net— — — 11 — 11 
Net loss— — — — (147,644)(147,644)
Balance at September 30, 2021129,570 $967,159 $54,607 $(794)$(722,800)$298,172 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30,
20222021
(in thousands)(unaudited)
Cash flows used in operating activities:
Net loss$(82,134)$(147,644)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization2,487 2,030 
Upfront license and milestone expense— 10,000 
Share-based compensation expense25,398 22,666 
Write-down of inventory2,464 — 
Other, net587 1,005 
Net changes in operating assets and liabilities
Accounts receivable(26,356)(9,815)
Inventories, net(8,458)(5,366)
Prepaid expenses and other current assets(3,461)(6,541)
Non-current assets(830)247 
Accounts payable, accrued and other liabilities875 1,149 
Lease liabilities(551)499 
Net cash used in operating activities (89,979)(131,770)
Cash flows used in investing activities:
Purchase of investments(403,184)(342,831)
Proceeds from investments346,109 263,752 
Upfront lease payment(381)(11,838)
Upfront license payment— (6,000)
Purchase of non-current assets(158)(268)
Additions to internal use-software implementation costs— (1,198)
Net cash used in investing activities (57,614)(98,383)
Cash flows from financing activities
Proceeds from exercise of stock options and employee share purchase plan1,745 15,353 
Proceeds from exercise of warrants— 37 
Cash provided by financing activities 1,745 15,390 
Net decrease in cash, cash equivalents and restricted cash(145,848)(214,763)
Cash, cash equivalents and restricted cash, beginning of period231,900 272,350 
Cash, cash equivalents and restricted cash, end of period$86,052 $57,587 
Supplemental cash flow information
Cash received for interest$1,705 $671 
Cash paid for taxes$(779)$(236)
Cash paid for amounts included in the measurement of lease liabilities$(897)$(195)
Supplemental disclosure of noncash transactions
Initial recognition of operating lease right-of-use asset$— $419 
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash, cash equivalents$85,341 $57,587 
Restricted cash711 — 
Total cash, cash equivalents and restricted cash$86,052 $57,587 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.
On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.
On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
2.Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
5


The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $376.6 million as of September 30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.
Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
Restricted cash: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7 million and $0.3 million as of September 30, 2022 and December 31, 2021, respectively.
Major Customers: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September 30, 2022 and 74% for the nine months ended September 30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September 30, 2022 of the Company's total revenues.
In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.
Milestone Payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be
6

included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. As of September 30, 2022, we recognized $30.0 million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September 30, 2022 and December 31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September 30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September 30, 2022 and as of December 31, 2021.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.
Recently adopted accounting pronouncements
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.
In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.
3.    Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the
7

Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:
September 30, 2022
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security— 4,904 — 4,904 
Corporate bond— 98,068 — 98,068 
Commercial paper112,633 — — 112,633 
Treasury bill— 26,704 — 26,704 
Treasury bond— 44,553 — 44,553 
Yankee bond— 3,730 — 3,730 
Total financial assets$198,685 $177,959 $— $376,644 
December 31, 2021
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit— 3,140 — 3,140 
Corporate bond— 21,820 — 21,820 
Commercial paper206,724 — — 206,724 
Treasury bill— 2,494 — 2,494 
Total financial assets$438,624 $27,454 $— $466,078 
The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2022, and December 31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for 7 months and 8 months, respectively. These investments have an overall rating of A-1, or higher, by Moody’s, Standard & Poor’s and Fitch.
No credit loss allowance was recorded as of September 30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, “Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
8

4.    Cash, Cash Equivalents, Restricted Cash and Short-Term Investments
As of September 30, 2022 and December 31, 2021, the Company had $376.6 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September 30, 2022, $376.6 million were available-for-sale debt securities which are carried at fair market value. As of December 31, 2021, $446.9 million were classified as available-for-sale and $19.2 million were held-to-maturity.
September 30, 2022
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security4,900 4 — 4,904 
Corporate bond98,448 — (380)98,068 
Commercial paper112,833 — (200)112,633 
Treasury bill26,721 — (17)26,704 
Treasury bond44,670 — (117)44,553 
Yankee bond3,742 — (12)3,730 
Total cash, cash equivalents, restricted cash and short-term investments$377,366 $4 $(726)$376,644 
December 31, 2021
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit3,144 — (4)3,140 
Corporate bond2,592 — (1)2,591 
Commercial paper206,764 — (40)206,724 
Treasury bill2,497 — (2)2,495 
Total$446,897 $— $(47)$446,850 
Total held to maturity securities at amortized cost19,228 
Total cash, cash equivalents, restricted cash and short-term investments$466,078 

As of September 30, 2022 and December 31, 2021, accrued interest receivable from the investments were $0.7 million and $0.1 million, respectively. During the three and nine months ended September 30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September 30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2022 and 2021.

The Company's short-term investments as of September 30, 2022 mature at various dates through June 2023.

5.    Inventories, net

Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor.

9

The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September 30, 2022, we have recorded reserves of finished goods inventories of approximately $2.7 million which were primarily related to process validation batches used for FDA approval.

The components of inventory, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Raw materials$2,217 $2,217 
Work in process20,150 12,566 
Finished goods2,953 4,543 
Total inventories$25,320 $19,326 


6.Prepaid Expenses
Prepaid expenses are as follows:

(in thousands)September 30, 2022December 31, 2021
Prepaid assets$5,725 $5,316 
Prepaid deposits3,582 4,762 
Prepaid insurance2,852 1,632 
Total prepaid expenses$12,159 $11,710 


7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2022
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,473 $(1,249)$224 
Acquired intellectual property and reacquired rights15,126 (9,580)5,546 
Internal-use software implementation costs2,873 (1,804)1,069 
$19,472 $(12,633)$6,839 
December 31, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,176)$295 
Acquired intellectual property and reacquired rights15,126 (8,804)6,322 
Internal-use software implementation costs2,873 (1,086)1,787 
$19,470 $(11,066)$8,404 
Amortization expense for the three months ended September 30, 2022 and 2021 was $0.5 million for both periods and for the nine months ended September 30, 2022 and 2021 was $1.6 million for both periods.

10

8.    Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Construction in progress$217 $393 
Leasehold improvements2,978 2,978 
Office equipment645 645 
Furniture976 976 
Computer equipment251 262 
5,0675,254
Less accumulated depreciation(1,309)(836)
Property and equipment, net$3,758 $4,418 
9.    Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.

During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.

On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $0.3 million of CIP cost that was related to the new corporate headquarters.

On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&A.
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.2 million included in the condensed consolidated balance sheets. As of December 31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
As of September 30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&A. The lease is not material to the Company's financial position.
11

The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for the three and nine months ended September 30, 2022 and September 30, 2021 are $0.2 million and $0.8 million for both periods respectively.
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2022:
As of September 30, 2022
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases8.95.22%
The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2022$263 
20231,061 
20241,085 
20251,110 
20261,135 
Thereafter5,638 
Total future minimum lease payments 10,292 
Less: lease imputed interest(2,104)
Total future minimum lease payments$8,188 
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0 million. The first capital expenditure payment was made in February 2021 of $11.8 million (CHF 10.5 million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $73.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9 million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1 million.
12

10.Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2022December 31, 2021
Employee accruals$16,511 $18,278 
Commercial accruals9,140 5,916 
Accrued R&D projects8,995 6,412 
Other accrued liabilities5,411 3,527 
Income taxes payable66 814 
Total accounts payable and accrued liabilities$40,123 $34,947 


11.Deferred Compensation and Other Non-current Liabilities

The Company recorded other non-current liabilities of $15.8 million and $16.0 million as of September 30, 2022 and December 31, 2021, respectively. The balance as of September 30, 2022 and December 31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.
12.License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.

As part of the agreement, the Company received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.

In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.

On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. The approval triggered a $30.0 million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September 30, 2022 and was subsequently received on October 31, 2022.

For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.4 million, respectively, of collaboration service revenue from Otsuka.

Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0 million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.
13

13.Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2022202120222021
Net loss$(8,989)$(50,255)$(82,134)$(147,644)
Weighted average common shares outstanding141,856 128,443 141,831 128,084 
Net loss per common share (expressed in $ per share)$(0.06)$(0.39)
(0.58)
(1.15)
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Nine months ended
September 30,
(in thousands)20222021
Stock options14,299 12,837 
Unvested performance awards— 857 
Unvested restricted units2,098 201 
Warrants— 1,012 
16,397 14,907 

14.Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.
During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month Offering Period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price.

As a result of the modification, $475 thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new 12 month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new 12 month offering period; therefore, the modification also resulted in a “repurchase for no consideration” under ASC 718. The Company recognized an additional $651 thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.
In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.
Stock Options

14

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2022 and September 30, 2021:
20222021
Annualized volatility70 %66 %
Risk-free interest rate2.01 %0.38 %
Expected life of options in years5.0 years4.0 years
Estimated forfeiture rate12.1 %8.9 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.60 $6.64 

The following table summarizes the option award activity for the nine months ended September 30, 2022:

September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 202112,074 $12.84 
Granted3,809 11.25 
Exercised(77)6.47 
Forfeited(1,507)14.63 
Outstanding - September 30, 202214,299 $12.26 
Performance Awards and Restricted Stock Units
On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.
On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant.
During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.
15

The following table summarizes the PA and RSU activity for the nine months ended September 30, 2022:
September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2021347 $13.33 
Granted2,311 11.26 
Vested(305)14.17 
Forfeited(255)12.39 
Outstanding - September 30, 20222,098 $11.04 
Compensation Expense
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2022 and September 30, 2021 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2022202120222021
Research and development$1,489 $1,038 $3,531 $3,201 
Selling, general and administrative6,625 6,000 21,480 19,189 
Capitalized under inventories206 54 387 276 
Share-based compensation expense$8,320 $7,092 $25,398 $22,666 
As of September 30, 2022, there was $33.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.

15.Income Taxes

The effective tax rates for the three and nine months ended September 30, 2022 and September 30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $1.0 million for the three and nine months ended September 30, 2022. The Company recognized an income tax expense of approximately $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.

Uncertain Tax Positions

The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September 30, 2022.
16.Related Party Transactions
ILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $6.0 million upon achievement of specific milestones. The amount payable to ILJIN is nil as of September 30, 2022 and December 31, 2021.
17.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies
16

will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and the quarterly report for the quarter ended September 30, 2022.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
18.Subsequent Events
The Company’s Compensation Committee granted 4 new employees an aggregate of 20,800 inducement stock options and an aggregate of 12,500 inducement RSUs. The options have a per share exercise price of $7.52, the closing price of Aurinia's common stock on September 30, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).
On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D., Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022.

Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.
17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; and our potential to receive certain payments and royalties under our agreement with Otsuka; and that an IND is expected to be submitted for AUR200 and AUR300 in 2023. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next few years; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2021 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 28, 2022 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, we introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. We continue to conduct pre-clinical, clinical, and regulatory activities to support the LUPKYNIS development program as well as our other assets. We engaged with Otsuka as a collaboration partner for development and commercialization of LUPKYNIS in the Otsuka Territories.
LUPKYNIS is an orally administered CNI immunosuppressant that has been demonstrated to improve near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) (although MMF is not currently approved as such) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can protect against proteinuria. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including uveitis,
18

keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation.
Aurinia announced during the fourth quarter of 2021 the initiation of ENLIGHT-LN, a U.S. based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. During the first quarter of 2022, we began actively enrolling patients.
On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.
On September 15, 2022, the EC granted marketing authorization of LUPKYNIS. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. The approval triggered a $30.0 million milestone payment to the Company, which was recognized as collaboration revenue in the three and nine months period ended September 30, 2022. We continue to progress with regulatory approval with Otsuka on the other Otsuka Territories.
Critical Accounting Policies and Significant Judgments and Estimates
Except as described below, there have been no material changes to the Company’s critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2021.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.
Milestone Payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based
19

royalties (and sales-based milestones) will be recognized when the related sales occur. As of September 30, 2022, we recognized $30.0 million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.

Results of Operations
Three and Nine Months ended September 30, 2022 compared to Three and Nine Months ended September 30, 2021
The following table sets forth our results of operations for the three and nine months ended September 30, 2022 and September 30, 2021.
Three months ended September 30,Nine Months Ended September 30,
20222021Change20222021Change
(in thousands)(in thousands)
Revenue
Product revenue, net$25,502 $14,638 $10,864 $75,142 $22,113 $53,029 
License and collaboration revenue30,277 29 30,248 30,453 88 30,365 
Total revenue, net55,779 14,667 41,112 105,595 22,201 83,394 
Operating expenses
Cost of sales2,447 254 2,193 4,302 610 3,692 
Selling, general and administrative52,169 44,645 7,524 148,898 128,772 20,126 
Research and development10,973 20,066 (9,093)35,118 39,990 (4,872)
Other (income) expense, net(311)55 (366)647 859 (212)
Total cost of sales and operating expenses65,278 65,020 258 188,965 170,231 18,734 
Loss from operations(9,499)(50,353)40,854 (83,370)(148,030)64,660 
Interest income1,464 106 1,358 2,209 420 1,789 
Net loss before income taxes(8,035)(50,247)42,212 (81,161)(147,610)66,449 
Income tax expense954 8 946 973 34 939 
Net loss$(8,989)$(50,255)$41,266 $(82,134)$(147,644)$65,510 
Revenues
Total net revenue was $55.8 million and $14.7 million for the three months ended September 30, 2022 and September 30, 2021, respectively. Total revenue was $105.6 million and $22.2 million for the nine months ended September 30, 2022 and September 30, 2021, respectively.
The increase in both periods is primarily due to the recognition of a $30.0 million regulatory milestone from Otsuka following the EC marketing authorization of LUPKYNIS in September 2022, coupled with an increase in product sales to our two main customers for LUPKYNIS driven predominantly by further penetration in the lupus nephritis market.
Cost of Sales
Cost of sales were $2.4 million and $0.3 million for the three months ended September 30, 2022 and September 30, 2021, respectively. Cost of sales were $4.3 million and $0.6 million for the nine months ended September 30, 2022 and September 30, 2021, respectively. The increase for both periods was primarily due to an increase in product related revenue, coupled with an increase in our safety stock inventory reserves.
Gross margin for the three months ended September 30, 2022 and September 30, 2021 was approximately 96% and 98% respectively. Gross margin for the nine months ended September 30, 2022 and September 30, 2021 was approximately 96% and 97% respectively.
20

Selling, General and Administrative Expenses
SG&A expenses increased to $52.2 million for the three months ended September 30, 2022 compared to $44.6 million for the three months ended September 30, 2021. For the nine months ended September 30, 2022 and September 30, 2021, SG&A expenses were $148.9 million and $128.8 million, respectively. SG&A expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2022202120222021
Salaries, incentive pay and employee benefits$20,422 $19,981 $62,487 $58,723 
Professional fees and services17,920 13,110 44,487 34,536 
Share-based compensation expense6,625 6,000 21,480 19,189 
Other corporate costs4,093 3,821 12,091 11,155 
Travel, trade shows and sponsorships3,109 1,733 8,353 5,169 
$52,169 $44,645 $148,898 $128,772 
The primary drivers for the increase in SG&A expense for the three and nine months ended September 30, 2022 as compared to the same periods ended September 30, 2021 were an increase in professional fees and services related to corporate legal matters, and travel and sponsorships to support the commercialization of LUPKYNIS. For the nine months ended September 30, 2022, salaries, incentive pay and employee benefits also increased due to employee related expenses such as increased headcount, promotions and inflation.
Research and Development Expenses
R&D expenses were $11.0 million and $20.1 million for the three months ended September 30, 2022 and September 30, 2021, respectively. For the nine months ended September 30, 2022 and September 30, 2021, R&D expenses were $35.1 million and $40.0 million, respectively. R&D expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2022202120222021
Contract research organizations (CRO) and developmental expenses$3,075 $15,873 $15,460 $25,579 
Clinical supply and distribution3,077 872 6,173 3,242 
Salaries, incentive pay and employee benefits3,159 2,070 9,429 7,807 
Share-based compensation expense1,489 1,038 3,531 3,201 
Other costs173 213 525 161 
$10,973 $20,066 $35,118 $39,990 

The primary driver for the decrease for the three and nine months ended September 30, 2022 as compared to the same periods ended September 30, 2021 were due to the upfront license and accrued milestone expense for AUR300 from the periods ended September 30, 2021 offset year to date by additional developmental expenses related to AUR200 and AUR300 for the periods ended September 30, 2022. In accordance with U.S. GAAP, AUR300 was recorded as an asset acquisition during the period ended September 30, 2021.

Interest Income

Interest income was $1.5 million and $0.1 million for the three months ended September 30, 2022 and September 30, 2021, respectively. Interest income was $2.2 million and $0.4 million for the nine months ended September 30, 2022 and September 30, 2021, respectively. The increase in both periods is due to higher yields on our investments as a result of increasing interest rates.

21

Liquidity and Capital Resources
As of September 30, 2022, we had cash, cash equivalents and restricted cash and investments of $376.6 million compared to cash, cash equivalents and restricted cash and investments of $466.1 million at December 31, 2021. The decrease in cash, cash equivalents and restricted cash and investments is primarily related to the continued investment in commercialization activities, advancement of our pipeline and a payment for the achievement of a one-time milestone, partially offset by an increase in cash receipts from sales of LUPKYNIS. Cash, cash equivalents and restricted cash and investments are primarily held in U.S. dollars. As of September 30, 2022 and December 31, 2021, we had working capital of $417.9 million and $472.7 million, respectively.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards the development of our AUR200 and AUR300 assets. Taking into consideration the cash and cash equivalents and investments as of September 30, 2022, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, advancing our R&D programs and funding our working capital obligations for at least the next few years.

Cash Flow Summary
The following table summarizes our cash flows for the nine months ended September 30, 2022 and September 30, 2021:
Nine Months Ended September 30,
(in thousands)20222021
Net cash (used in) provided by:
Operating activities$(89,979)$(131,770)
Investing activities(57,614)(98,383)
Financing activities1,745 15,390 
Net decrease in cash and cash equivalents$(145,848)$(214,763)

Net cash used in operating activities was $90.0 million for the nine months ended September 30, 2022 compared to $131.8 million for the nine months ended September 30, 2021. Net cash used in both periods was primarily related to the continued investment in commercialization activities, payments made for our ongoing post approval obligations, advancement of our pipeline, and inventory purchases partially offset by cash receipts from sales of LUPKYNIS. The decrease in net cash is primarily due to an increase in cash receipts from sales of LUPKYNIS.
Cash used in investing activities during the nine months ended September 30, 2022 was $57.6 million compared to cash used in investing activities of $98.4 million during the nine months ended September 30, 2021. The decrease was primarily related to the timing of purchases of investments offset by proceeds of maturities of investments and a nonrecurring upfront lease and license payment made during the nine months ended 2021.
Cash provided by financing activities during the nine months ended September 30, 2022 was $1.7 million compared to cash provided by financing activities of $15.4 million during the nine months ended September 30, 2021. The decrease was primarily due to less proceeds from the exercise of stock options.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021.
22

Item 3. Quantitative and Qualitative Disclosures About Market Risks
Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by our Board of Directors, with oversight provided by the Audit Committee of our Board of Directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest Rate Risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct
operations on a day-to-day basis. As of September 30, 2022, our investment portfolio includes cash, cash equivalents, restricted cash and investments of $376.6 million that earn interest at market rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of highly rated instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of September 30, 2022, these instruments have a maturity of less than a year.

As of September 30, 2022, a hypothetical decrease of 100 basis points on the interest rates of our investments would result in $2.9 million less interest in our portfolio.

Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.

Foreign Currency Risk

We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound, which could affect our operating and financial results. The majority of our cash is held in U.S. dollars and a Canadian denominated bank account. As of September 30, 2022, a 10% increase of the Canadian dollar would have increased the net loss by $0.1 million assuming all other variables remained constant. An assumed 10% weakening of the Canadian dollar would have had an equal but opposite effect to the amounts shown above, on the basis all other variables remain constant. There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of September 30, 2022.

Inflation Risk

Inflation has increased during the periods covered by this Quarterly Report and is expected to continue to increase for the near future. Inflation generally affects us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. In addition, due to the increasing interest rates and market volatility, our investment portfolio may have higher yields with short-term maturities of nine months or less which could in turn increase the risk of realized losses on our investments if we were to sell before maturity.

Credit Risk

Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions and invest the excess cash in highly rated investments. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

We are subject to credit risk in connection with our accounts receivable due from our two customers and our collaboration partner which accounted for 99% of our net trade accounts receivable balances as of September 30, 2022. We monitor economic conditions, the creditworthiness of our customers and government regulations and funding, both domestically and abroad. We regularly communicate with our customers regarding the status of receivable balances. During the quarter ended September 30, 2022, we did not recognize any allowance for doubtful accounts receivable related to credit risk for our customers.
Item 4. Controls and Procedures.
23

Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of September 30, 2022, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
24

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
There are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 or the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above except as mentioned below. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
In response to the ongoing armed conflict in Ukraine, the U.S. government, numerous state governments, the EU and other countries in which we conduct business have imposed a wide range of economic sanctions that restrict commerce and business dealings with Russia, certain regions of Ukraine and certain entities. This conflict may also precipitate or amplify the other risks described herein and in our Annual Report on Form 10-K for the year ended December 31, 2021, Part I. Item A. Risk Factors including risks relating to cyber security, global economic conditions and supply chains which could adversely affect our business, operations and financial condition and results.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following exhibits are filed as part of this report:
25

Exhibit
Number		Description
3.1
3.2
10.22+#
10.23+#
10.24+#*
10.25+#*
10.26+#*
10.46#
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
**Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.
+Indicates a management contract of compensatory plan.
#Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because they are not material and are the type that Aurinia treats as private or confidential.

26

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
November 2, 2022By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
November 2, 2022By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
27
 EX-10.24 2 exhibit1024separationagree.htm EX-10.24 Document
Exhibit 10.24
CONFIDENTIAL SEPARATION AGREEMENT,
GENERAL RELEASE AND COVENANT NOT TO SUE


This is a Confidential Separation Agreement, General Release and Covenant Not to Sue (“Agreement”) between Aurinia Pharma U.S., Inc. (“Aurinia”), on the one hand, and Max Colao (“Mr. Colao”), on the other hand. Aurinia and Mr. Colao shall collectively be referred to herein as the “Parties”.

WHEREAS, Mr. Colao had been an employee of Aurinia; and

WHEREAS, Mr. Colao’s employment with Aurinia ended on or about July 22, 2022; and

WHEREAS, the Parties desire to amicably end their employment relationship and wish to formalize their agreement regarding the termination of their relationship; and

WHEREAS, the Parties desire to document the terms of their separation, with the Parties agreeing that Aurinia admits no wrongdoing, fault, or liability whatsoever, and that nothing herein shall be construed or interpreted as an admission of any wrongdoing, fault or liability of Aurinia;

NOW THEREFORE, in consideration of the mutual promises, covenants, and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties agree as follows:
1.    Payments by Aurinia: Provided Mr. Colao has complied and continues to comply with his obligations as set forth in this Agreement, Aurinia shall make the following payments:
a)    Severance Payment: A one-time, lump sum payment in the gross amount of Four Hundred, Eighty-Eight Thousand, Eight Hundred, Thirty-Five Dollars and Zero Cents ($488,835.00), payable to Mr. Colao, less income tax withholding and other standard payroll deductions.
b)    2022 Performance Bonus Payment: A one-time, lump sum payment in the gross amount of Two hundred, Forty-Four Thousand, Four Hundred, Seventeen Dollars and Fifty Cents ($244,417.50), payable to Mr. Colao, less income tax withholding and other standard payroll deductions. This payment will be made within [redacted] of the earlier of (i) [redacted], or (ii) the date that such 2022 performance bonuses are generally otherwise paid to Aurinia’s executive officers for objectives met in calendar year 2022.
2.    COBRA Payments: Assuming Mr. Colao’s proper election of and eligibility for COBRA coverage, Aurinia shall pay on his behalf the premium costs for COBRA continuation coverage for medical benefits, for [redacted].  It is understood and agreed that any period during which Aurinia reimburses Mr. Colao’s COBRA premium costs pursuant to the preceding sentence shall count toward the COBRA period to which Mr. Colao shall be entitled by law.  Such payments will be made directly by Aurinia to Aurinia’s third-party administrator of COBRA.  To receive this benefit, Mr. Colao must elect to continue his current health coverage under COBRA by completing and signing the necessary forms, which have been or will be mailed to him directly and returning them in a timely fashion.  This benefit is subject to the applicable terms and conditions of the benefit plan(s) in effect during the period of time in which the benefit(s) is provided and nothing herein shall affect Aurinia’ ability to modify, terminate or otherwise change any benefit plan it has in effect at any given time, to the extent permitted by law, and such changes shall be effective immediately, including any changes to the employee
Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.

share of the premium.  Mr. Colao will be responsible for paying the total cost of continuing insurance coverage under COBRA before and after the payments made by Aurinia and all such payments must be mailed directly to the third-party administrator of COBRA.
3.    Taxes: Mr. Colao agrees that he shall be solely and entirely responsible for the payment and discharge of all federal, state and local taxes, if any, which may at any time be found to be due upon or as a result of the payments or benefits described herein (though Aurinia shall withhold for all employer obligations for taxes, including for FICA, Medicare, FUTA, SUTA or similar obligations on an employer) and agrees to indemnify and hold harmless Aurinia against any claim or liability for any such taxes as described above and any related penalties and/or interest, in the event any such taxes, penalties and/or interest be assessed by the United States Internal Revenue Service and/or any other state or local taxing authority. Mr. Colao also agrees to cooperate with Aurinia in the event of a tax audit involving the payments under this Agreement. Mr. Colao agrees to cooperate fully with the designation and payments set forth above and complete any paperwork necessary as a condition for Aurinia’s payments pursuant to this Agreement, including, but not limited to, completion of any tax forms (such as a W-4 and/or W-9) or other forms necessary for legal compliance or at the request of Aurinia, either before or after such payments. Aurinia may issue any tax forms and make reports of any such payments or benefits, within its sole discretion and as it deems necessary and/or appropriate.
4.    No Further Benefits: Mr. Colao expressly admits, agrees, and acknowledges that the benefits described in this Agreement are not benefits to which he is otherwise entitled, and that he receives none of the benefits in this Agreement unless he signs this Agreement and does not revoke it, pursuant to the revocation provision below. Mr. Colao further expressly admits, agrees and acknowledges that he is not entitled to any other or further compensation, remuneration, commissions, bonuses, benefits, reimbursement, vacation/PTO pay, payments, options, stock, or other equity issue of or from Aurinia. Nothing in this Agreement affects any vested benefits Mr. Colao has under any retirement plan or any deferred compensation plan. Any remaining continuation and/or conversion rights to health or other insurance benefits, if any, will be as provided by the terms and conditions of those plans and applicable law. For purposes of any 401(k) plan or other retirement plans, the payments described herein do not constitute salary and wages to which existing employee contribution elections and/or employer match, if any, apply.
5.    General Release of Aurinia: Mr. Colao agrees to and hereby does, for himself and for each of his family members, heirs, representatives, executors, administrators and assigns, and each person or entity acting by or through any of them, forever and irrevocably fully release and discharge Aurinia and the Releasees (as defined below), of and from any and all grievances, disputes, liens, suits, judgments, proceedings, charges, lawsuits, claims, awards, demands, debts, defenses, actions or causes of action, rights, obligations, damages, and liabilities whatsoever which he now has, has had, or may have, whether the same be known or unknown, suspected or unsuspected, at law, in equity, or mixed, in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction which occurred or allegedly occurred on or before the date this Agreement is signed by Mr. Colao. This is a General Release. By signing this Agreement, Mr. Colao is agreeing to forego all claims or potential claims against Aurinia and the Releasees. Mr. Colao agrees that this release will extinguish all claims which have arisen at any time up to the time he signs this Agreement. Mr. Colao expressly acknowledges that this General Release includes, but is not limited to, any claims arising out of or relating in any way to his employment with Aurinia, the ending of his employment with Aurinia, and all issues raised or which could have been raised in any litigation against Aurinia and/or the Releasees. Notwithstanding anything in this Agreement to the contrary, this Agreement will not waive (a) any rights expressly provided for in this Agreement or (b) any rights that, as a matter of law, cannot be waived. If any claim is not subject to release, to the extent permitted by law, Mr. Colao waives any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class,
2

collective or multi-party action or proceeding and to collect or receive any money from Aurinia based on such a claim in which Mr. Colao or any other Releasee identified in this Agreement is a party. Mr. Colao agrees to this General Release knowingly and voluntarily.
6.    Further Description of General Release: Mr. Colao expressly acknowledges that his General Release of Aurinia and the Releasees includes, but is not limited to, any claims constituting or based on tort, contract, implied contract, defamation, libel, slander, intentional infliction of emotional distress, wrongful or abusive discharge, negligence, interference with contract or employment, assault and battery, personal injury, whistle-blowing, implied covenant of good faith and fair dealing, fraud, stock fraud, equity, any short-term or long-term disability benefits plan, intellectual property, spoliation of evidence, statute or common law, severance pay, equity compensation and/or fringe benefits, attorneys’ fees, vacation pay, bonus, sales commissions, debts, accounts, compensatory damages, punitive or exemplary damages, expense reimbursement, or liquidated damages, arbitration claims, claims under any local, state or federal law, wage and hour law, wage collection law or labor relations law, and any claims of discrimination or harassment on the basis of age, race, sex, religion, disability, pregnancy, sexual orientation, national origin, ancestry, citizenship, retaliation or any other claim under any federal, state or local employment-related, human rights, civil rights, or employment discrimination statute, rule, regulation or ordinance, including, but not limited to, the following: the Civil Rights Acts of 1964 and 1991, as amended; Section 1981 of the Civil Rights Act of 1866; the Equal Pay Act of 1963; the Family and Medical Leave Act; the Age Discrimination In Employment Act (ADEA); the Americans With Disabilities Act; the Rehabilitation Act of 1973; the Employee Retirement Income Security Act; the Consolidated Omnibus Budget Reconciliation Act of 1985; The Worker Adjustment and Retraining Notification Act; The False Claims Act; The Sarbanes-Oxley Act of 2002; the Fair Labor Standards Act of 1993; the Lilly Ledbetter Fair Pay Act of 2009, as amended; the Occupational Safety and Health Act; the Maryland Fair Employment Practices Act (MD State Govt. Code Sec. 20-601 et seq.); the Maryland Wage Payment and Collection Act; the Maryland Wage and Hour Law; and any other claim under any law, regulation, or ordinance prohibiting employment discrimination or relating to employment. By signing this Agreement, Mr. Colao agrees that he has not suffered any injuries or occupational diseases relating to or arising out of his employment with Aurinia which would be compensable under the state workers’ compensation act and that he has received all salary and wages (including any commissions or overtime pay for all hours worked, as applicable) and leave to which he was entitled as an employee of Aurinia and that he is not aware of any facts or evidence of any discrimination or retaliation by Aurinia. Further, by signing this Agreement, Mr. Colao also expressly acknowledges and represents that he is not currently aware of any facts or circumstances constituting a violation of the Family and Medical Leave Act of 1993 or the Fair Labor Standards Act, or any similar state law. Mr. Colao specifically acknowledges that he releases and waives any claim for any attorneys’ fees, costs and expenses, including any attorneys’ liens for fees.
7.    Release of Unknown Claims by Mr. Colao: Mr. Colao understands and agrees that the claims released herein by him are intended to and do include any and all claims of every nature and kind whatsoever, known or unknown, suspected or unsuspected, which he has or may have against any person or entity he released above and he expressly consents that this Agreement shall be given full force and effect according to each and all of its expressed terms and provisions, including as well those relating to unknown and unspecified claims, charges, demands, suits, actions, causes of action and debts, if any, and those relating to any other claims, charges, demands, suits, actions, causes of action and debts hereinabove specified. Mr. Colao acknowledges that he is aware that he may hereafter discover claims or facts in addition to, or different from, those which he now knows or believes to exist with respect to the subject matter covered by this Agreement and which, if known or suspected at the time of executing this Agreement, may have materially affected this Agreement or his decision to enter into it.
3

Nevertheless, he hereby waives any rights, claims or causes of action that might arise as a result of such different or additional claims or facts.
8.    Agreement Not to File Actions: Mr. Colao agrees not to file, join in or prosecute further any lawsuits against Aurinia and/or any of the Releasees, concerning any matter in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction which occurred or allegedly occurred on or before the date this Agreement is signed by Mr. Colao. By signing this Agreement, Mr. Colao agrees not to sue Aurinia and/or any of the Releasees for anything which has been released pursuant to this Agreement. Nothing in this Agreement prohibits or prevents Mr. Colao from filing a charge with or participating, testifying, or assisting in any investigation, hearing, whistleblower proceeding, or other proceeding before any federal, state, or local government agency (e.g. EEOC, NLRB, SEC, etc.), nor does anything in this Agreement preclude, prohibit, or otherwise limit, in any way, his rights and abilities to contact, communicate with, report matters to, or otherwise participate in any whistleblower program administered by any such agencies. However, to the maximum extent permitted by law, Mr. Colao agrees that if such an administrative claim is made, Mr. Colao shall not be entitled to recover any additional monetary relief or other individual remedies. Nothing in this Agreement will interfere with the right of Mr. Colao to challenge the enforceability of the release of claims in this Agreement under the Age Discrimination in Employment Act or to enforce the terms of this Agreement. Mr. Colao represents and warrants that he does not presently have on file any claim, charge, grievance, or complaint against Aurinia or any of the Releasees in or with any administrative, state, federal, or governmental entity, agency, board, or court or before any other tribunal, panel or arbitrators, public or private, based upon any actions or omissions by Aurinia or any of the Releasees occurring prior to his execution of this Agreement.
9.    Releasees: Without limiting the generality of the General Release, Mr. Colao specifically acknowledges and agrees that he is knowingly and voluntarily releasing each and all of the following persons, companies, and entities from any and all claims he has or may have: Aurinia Pharma U.S., Inc., and any and all past, present, and/or future parent, subsidiary, affiliate, related business entity, employee benefit plan or fund, or any insurers, and its and their respective past, present, and/or future officers, Board members, directors, personnel, employees, managers, partners, administrators, associates, agents, predecessors, successors, purchasers, attorneys, assigns, members, and representatives and any person or entity acting by or through any of them, as well as any co-employer or professional employer organization (collectively known herein as “Releasees”).
10.    Testimony by Subpoena: Mr. Colao further agrees that in the event that he is required by subpoena to provide testimony to any person or entity who has filed or who seeks to file or prosecute any grievance, claim, charge, complaint or lawsuit against Aurinia or any Releasee, he will provide written notice of such subpoena to Aurinia within 48 hours of receipt of such subpoena.
11.    No Admission of Liability: Mr. Colao expressly acknowledges and agrees that this Agreement is not an admission of liability under any federal, state, or local statute, regulation, or ordinance, or breach of any contract, duty or obligation owed by Aurinia to Mr. Colao and is not otherwise an admission by Aurinia, and that Aurinia does not admit but denies any violation of his legal rights.
12.    Not a Prevailing Party: Mr. Colao agrees that he shall not be regarded as the prevailing party for any purpose, including, but not limited to, determining responsibility for or entitlement to attorneys’ fees or costs, under any statute or otherwise.
4

13.    Duty to Cooperate: Mr. Colao agrees that, in the event Aurinia is or becomes a party or witness to any actual or threatened legal proceeding regarding any matter that arose, concerns or occurred during the term of his employment with Aurinia, he shall make himself reasonably available to and cooperate with Aurinia and its counsel in such proceedings, without further payment or compensation. Mr. Colao further agrees to answer any practical administration questions which may arise and to make himself reasonably available to assist Aurinia in its transition following his employment and to cooperate with any other reasonable request by Aurinia which may require his services after the ending of his employment. The Parties agree that, for the purpose of this Paragraph, the transition period shall be [redacted] following the Effective Date of this Agreement. Mr. Colao will not seek or be entitled to any additional compensation for such assistance or cooperation.
14.    No Future Employment: Mr. Colao specifically acknowledges that his employment with the Company is irrevocably severed and his signing of this Agreement shall have the legal effect of forever surrendering, waiving and withdrawing any request or claim he has made, may have made, or could make for continuing employment with Aurinia beyond the last day of employment. Mr. Colao acknowledges that because of circumstances unique to him including, but not limited to, irreconcilable differences with Aurinia, he is not qualified to hold any position with Aurinia or any of the Releasees, now or in the future, and, therefore, shall not apply in the future for or hold employment with Aurinia or any of the Releasees. In the event that Mr. Colao should unknowingly seek/obtain employment with Aurinia or any of the Releasees, he will, immediately upon obtaining knowledge of his breach of this Paragraph, remedy said breach by either withdrawing such application and/or resigning his employment and that failure to do so shall subject him to immediate termination without notice or cause as a remedy for breach of this Agreement. Mr. Colao agrees that this is a negotiated, non-retaliatory settlement term.
15.    Agreement is Confidential: Except as otherwise stated in this Paragraph, Mr. Colao specifically agrees to keep the existence and terms of this Agreement, the circumstances giving rise to its execution, the negotiations leading thereto and all matters relating to the allegations raised or which could have been raised in any litigation completely confidential and secret. He expressly covenants not to display, publish, disseminate, or disclose any such information to any person or entity, except to his attorneys, tax advisor, accountant, spouse, or if necessary to comply with a court order or to enforce the terms of this Agreement. Mr. Colao will instruct such person(s) to keep the information confidential pursuant to his obligations under this Paragraph and he agrees that any unauthorized disclosure by any such persons to any other person, entity or organization shall constitute a breach of this Paragraph by Mr. Colao. Mr. Colao may respond to unsolicited inquiries concerning his employment separation with Aurinia by stating only that his “employment ended amicably with Aurinia,” and may provide general information about his position and duties while at Aurinia. Mr. Colao agrees not to disparage or defame, or otherwise communicate any negative information about Aurinia and/or the Releasees in any such response. Mr. Colao warrants and represents that prior to his execution of this Agreement, he did not disclose, directly or indirectly, any of the terms or promises of this Agreement or the payments offered him to any person, including other current or former employees of Aurinia, other than his attorneys, tax advisor, accountant and spouse. If required by a valid court-issued subpoena, Mr. Colao may produce a copy of this Agreement provided that he gives written notice of such subpoena to Aurinia within [redacted] of receipt of such subpoena and allows Aurinia a reasonable opportunity to move for a protective order or to otherwise quash the subpoena. Mr. Colao may also discuss the terms of his separation with official law enforcement, if required to do so pursuant to a subpoena, provided he gives notification to Aurinia within [redacted] of being requested to provide such information. Nothing in this Agreement prohibits or limits Aurinia’s right to reveal the existence, terms, and conditions of this Agreement within its organization, to its attorneys, to its financial advisors and accountants or as otherwise judged appropriate by Aurinia, and to fulfill reporting obligations under applicable laws and requirements.
5

16.    Confidential Information: Mr. Colao agrees that all information and know-how, regardless of whether in writing, of a private, secret or confidential nature concerning Aurinia’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of Aurinia and that he will not use or disclose to any person or entity or aid others in obtaining or using any such information. By way of illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects, developments, plans, research data, financial data, personnel data, computer programs, computer software or code, information about actual or prospective customers, supplier lists and any other confidential business information. Mr. Colao will not disclose, at any time, any Proprietary Information to others outside Aurinia or use the same for any unauthorized purposes without prior written approval by an officer of Aurinia unless and until such Proprietary Information has become public knowledge without fault by Mr. Colao. Accordingly, Mr. Colao agrees to keep confidential any trade secret, business or Proprietary Information which Mr. Colao acquired during his employment with Aurinia, including, but not limited to, any Aurinia marketing, technology, customer, or sales information, plans, or strategies. This is intended to cover any information of a nature not normally disclosed by Aurinia to the general public. If required by a valid court-issued subpoena, Mr. Colao may disclose Proprietary Information provided that he gives written notice of such subpoena to Aurinia within [redacted]of receipt of such subpoena.
17.    Return of Property: Mr. Colao agrees that within [redacted]of the Effective Date, he will return to Aurinia any and all property of Aurinia, including, but not limited to, any files and any documents prepared for or by Aurinia, whether or not prepared for or by Mr. Colao; computers; iPhones or similar devices; cellular phones; credit cards; files, books, binders, manuals, and other printed material; computer disks and software; files; and all other tangible and intangible property belonging to Aurinia and obtained by Mr. Colao in connection with his employment with Aurinia, including all copies of such property, in any form, electronic or otherwise. Mr. Colao agrees that no payment or any other benefit under this Agreement shall be made or given by Aurinia until and unless Mr. Colao has returned all property of Aurinia as required by this Paragraph. Mr. Colao also affirms that Aurinia is not in possession of any of his personal property.
18.    Non-Disparagement: Mr. Colao agrees that he will not communicate or make or cause, directly or indirectly, any other person or entity to communicate or make any adverse, derogatory, libelous, slanderous, defamatory or disparaging remarks, statements or communications about Aurinia or any of the Releasees, including the personal and/or business reputations, practices, products, services or conduct of Aurinia or any of the Releasees. For instance, and without limitation, Mr. Colao shall not post on any social media or disclose in any other format or manner any issues, concerns or problems regarding any Aurinia business or service or disparage any Releasee on any such internet website or posting.
19.    Breach of Agreement: Mr. Colao expressly agrees that a breach of any of the promises and covenants contained or referenced in this Agreement, including the filing of a lawsuit against Aurinia, shall be considered a material breach of the terms of this Agreement, and shall entitle Aurinia to recover from Mr. Colao any monies paid to him under this Agreement and Aurinia will have no further obligations to pay Mr. Colao any further compensation, as well as any and all remedies available at law and costs and reasonable attorneys’ fees incurred in enforcing any provision of or any right contained in this Agreement. However, nothing in this Agreement will interfere with his right to challenge the enforceability of the foregoing release of claims under the Age Discrimination In Employment Act, and Mr. Colao shall not be required to tender back the payments made to him under this Agreement nor be liable for the costs and attorneys’ fees that Aurinia and/or the Releasees incur in connection with a challenge by Mr. Colao of the foregoing release of claims pursuant to the Age Discrimination In Employment Act.
6

20.    No Transfer or Assignment: Mr. Colao represents and warrants that no person had or has or claims any interest in the claims referred to anywhere in this Agreement. He also represents and warrants that he has the sole right and exclusive authority to execute this Agreement and that he has the sole right to receive the consideration paid therefore. He also represents and warrants that he has not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity, any claim against Aurinia or any of the Releasees or portion thereof or interest therein, and will not assign or otherwise transfer, any claim or demand relating to any matter covered by this Agreement or the consideration to be paid pursuant thereto.
21.    Entire Agreement and Enforcement: The Parties agree that this Agreement shall be binding upon the assigns, heirs, executors, and administrators of Mr. Colao and shall inure to the benefit of the officers, directors, employees, agents, parents, affiliates, predecessors, successors, purchasers, assigns, and representatives of Aurinia, including Aurinia and the Releasees. This Agreement supersedes all prior agreements between the Parties, and this Agreement constitutes the entire agreement between the Parties and all previous discussions, promises, representations, and understandings relating to the topics herein discussed are hereby merged into this Agreement. The Parties agree that there are no additional promises or terms among the Parties other than those contained or referred to herein. Notwithstanding the above, any other any invention, confidentiality, non-competition, and/or non-solicitation agreements/provisions between Mr. Colao and Aurinia are hereby incorporated in this Agreement and remain enforceable notwithstanding this Agreement.
22.    Amendment and Notice: This Agreement may not be modified, waived or amended except in writing signed by each of the Parties wherein specific reference is made to this Agreement. Notification to Aurinia under this Agreement shall be via both written letter to counsel for Aurinia, Larry R. Seegull, Esq., Jackson Lewis P.C., 2800 Quarry Lake Drive, Suite 200, Baltimore, Maryland 21209, [redacted] and electronic mail to [redacted].
23.    No Waiver: The Parties recognize, acknowledge and agree that the failure by Aurinia to enforce any term of this Agreement shall not constitute a waiver of any rights or deprive Aurinia of the right to insist thereafter upon strict adherence to that or any other term of this Agreement, nor shall a waiver of any breach of this Agreement constitute a waiver of any preceding or succeeding breach. No waiver of a right under any provision of this Agreement shall be binding on Aurinia unless made in writing and signed by Aurinia.
24.    Governing Law: The validity and construction of this Agreement or of any of its terms or provisions shall be determined under the laws of the State of Maryland, regardless of any principles of conflicts of laws or choice of laws of any jurisdiction. Accordingly, Mr. Colao waives any right he may have to assert the applicability of another state’s law or to contest the application of the law of the State of Maryland. The exclusive jurisdiction and venue of any lawsuit arising under this Agreement shall be the State and Federal Courts in the State of Maryland having proper jurisdiction, and Mr. Colao hereby irrevocably agrees, acknowledges and submits to the exclusive jurisdiction and venue of such court for the purposes of any such lawsuit arising under this Agreement. Whenever in this Agreement the context may so require, the masculine gender shall be deemed to refer to and include the feminine and neuter, and the singular to refer to and include the plural, and vice versa. This Agreement has been freely negotiated by both Parties and therefore the language of all parts of this Agreement shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against any of the Parties, notwithstanding any statutory or common law provisions which would suggest otherwise.
25.    Reformation and Severability: Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law. If, however, any of the provisions contained in this Agreement is declared illegal, unenforceable, or
7

ineffective in a legal forum of competent jurisdiction, Mr. Colao agrees that such provision shall be modified and reformed, if possible, in order to achieve, to the extent possible, the intentions of the Parties, and, if necessary, such provision shall be deemed severable, such that all other provisions contained in this Agreement shall remain valid and binding; provided, however, that if any portion of the General Release is held to be invalid or unenforceable, then the entire Agreement, including any obligation for Aurinia to provide any payment or benefits hereunder, shall be voidable at the option of Aurinia.
26.    Consultation with Attorney: Mr. Colao is advised to consult an attorney regarding the terms of this Agreement before signing it, and states that he has consulted with his attorney regarding this Agreement, and had a full and fair opportunity to consult with any personal, family or professional advisors of his choosing regarding this Agreement, and that in executing this Agreement he has not relied upon any representations or statements by Aurinia or any of its respective agents, representatives, employees, or attorneys regarding the subject matter, basis, or effect of this Agreement. The Parties specifically agree and acknowledge that no court or agency must specifically approve this Agreement or its terms and conditions, including the release of any claims herein, for it to become effective.
27.    Offer Period and Effective Date: Pursuant to the Older Workers Benefit Protection Act, Mr. Colao acknowledges and represents that he waives his claims identified above herein knowingly and voluntarily and in exchange for consideration of value. Mr. Colao acknowledges and represents that he understands that he has twenty-one (21) days from his receipt of this Agreement to consider his decision to sign it. Mr. Colao acknowledges and understands that he may revoke this Agreement within seven (7) days following his execution of this Agreement. Revocation shall be made by delivering written notice of revocation to Larry Seegull, Esq. and must be received no later than the final day of the revocation period. Revocation by Mr. Colao under this paragraph shall be via electronic mail to [redacted] and/or written letter to Larry Seegull, Esq., Jackson Lewis P.C., 2800 Quarry Lake Drive, Suite 200, Baltimore, Maryland 21209, [redacted]. This Agreement shall not become effective or enforceable until the revocation period has expired and the Agreement has been timely returned to Aurinia, and no monies shall be paid to Mr. Colao if he exercises his right to revocation. Accordingly, the Effective Date of this Agreement shall be the eighth day following his signing of this Agreement, provided he has not revoked the Agreement previously and has timely returned the signed Agreement.
28.    Tax Code Compliance: This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any regulations and Treasury guidance promulgated thereunder. The immediately preceding sentence, however, shall not be construed as a guarantee by Aurinia of any particular tax effect to Mr. Colao under this Agreement.
29.    Full Defense: This Agreement may be pled as a full and complete defense to, and may be used as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by or on behalf of Mr. Colao in breach hereof.
30.    Counterparts, Facsimile and PDF Signature: This Agreement may be executed in counterparts, each of which will be deemed an original, but both of which together will constitute one and the same instrument. A facsimile, electronic, PDF or email copy of the signature of any signatory on this Agreement shall be deemed the equivalent of an original thereof.
31.    Headings: The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement or to define or limit the scope of any Paragraph of this Agreement.
8

MR. COLAO REPRESENTS THAT HE HAS READ THIS AGREEMENT, THAT BASED THEREON, HE UNDERSTANDS ALL OF ITS TERMS, AND THAT HE ENTERS INTO THIS AGREEMENT VOLUNTARILY AND WITH FULL KNOWLEDGE OF ITS EFFECT.

August 11, 2022                /s/ Max Colao                
Date                        Max Colao


                        


August 12, 2022            By:    /s/ Max Donley            
Date                        Aurinia Pharma U.S., Inc.




9
 EX-10.25 3 exhibit1025separationagree.htm EX-10.25 Document
Exhibit 10.25
image_0.jpg

PERSONAL AND CONFIDENTIAL


October 20, 2022

Neil Solomons
[redacted]

Dear Neil:
Re: End of Employment with Aurinia Pharmaceuticals Inc. (the “Company”)
Further to our recent discussions, as you are aware, the Company wished for you to begin to report to Volker Knappertz, Executive Vice President, Research and Development, pursuant to your current terms and conditions of employment (including with respect to compensation and benefits). We do not view this as a fundamental change to the terms and conditions of your employment and, in any event, as set out in your employment agreement with the Company dated September 12, 2012 (the “Employment Agreement”), you are required to report to such other person that the Board may otherwise determine from time to time. However, we understand that this is not an arrangement you wish to accept, and that you wish to end your employment.
As such, this letter confirms that you and the Company have mutually agreed that your employment with the Company will come to an end, effective October 31, 2022 (the “End Date”). This letter also sets forth details regarding the end of your employment and makes a without prejudice severance offer in exchange for a full and final Release in favour of the Company.
GENERAL
Working Notice and Statutory Payments
From now until the End Date (the “Working Notice Period”), you will be expected to perform your assigned duties and responsibilities to the best of your ability, and you will continue to receive your usual compensation and benefits, less applicable deductions, and withholdings.
Following the End Date, the balance of all outstanding wages, including any accrued and unused vacation pay, will be paid to you in a lump sum. Your accrued and unused vacation entitlements will be paid out on October 31, 2022, and are as follows:
    Accrued (unused) vacation = 240 hours ($52,873.97 CAD) (provided no vacation is taken between now and the End Date)
    Grandfathered vacation = 779.52 hours ($194,725.98 CAD)
These amounts are subject to the usual deductions, and you will be paid these amounts regardless of whether you accept the without prejudice severance offer detailed below.
Note that, in the event that you are terminated for just cause or resign from your employment prior to the end of the Working Notice Period, all payments and benefits will cease, and you will not receive any further compensation or pay in lieu, except as may be minimally required pursuant to the British Columbia Employment Standards Act.
Record of Employment
Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii)
would be competitively harmful if publicly disclosed.

After the end of the Working Notice Period, your Record of Employment will be submitted electronically to Service Canada, which you will be able to access online on the Service Canada website. We encourage you to visit the Service Canada website at: https://www.canada.ca/en/services/benefits/ei.html to familiarize yourself with the available Employment Insurance (EI) application process and support services offered by the Canadian Government.
Outstanding Business Expenses
After the end of the Working Notice Period, outstanding unreimbursed business expenses will be paid within the Company’s normal policies for expense reimbursement following submission of the expense report.
Return of Company Property
On or before the End Date, please return to the Company all its property, including, but not limited to, building access card, laptop, iPad, passwords, computer usernames, voicemail code, phone cards, company credit card, keys, internal policies, and other confidential business information and documents, and any other property belonging to the Company. Please also destroy or delete all tangible or electronic copies of any such property after returning it to the Company.
Confidentiality and Other Continuing Obligations
We wish to remind you that, despite the cessation of your employment with the Company, you continue to be bound by:
    The Confidentiality Agreement and Assignment of Inventions attached as Schedule C to the Employment Agreement;
    All restrictive covenants contained in the Employment Agreement, including paragraph 23 (Restrictive Covenant) of the Employment Agreement; and
    All fiduciary duties that arise from your employment.
The Company expects you to comply with these obligations, which survive the cessation of your employment.



Benefits

Subject to provider approval and the terms and conditions of the applicable plans, the Company will maintain your Medical, Dental, and Vision benefits until the earlier of:
i.     the date you obtain replacement benefits; or
ii.     twelve (12) months from the End Date,
after which time you will be responsible for obtaining your own replacement benefits.

Coverage for your Short Term & Long-Term Disability, Life Insurance, AD&D, Group Retirement Savings Plan, and all other benefits other than Medical, Dental, and Vision benefits, will terminate as of the End Date, October 31, 2022, and you will be responsible for obtaining your own replacement benefits.

There may be conversion options available to you through Sun Life that are subject to strict time limitations (e.g., within 31 days of your coverage termination date):

2


    Please call Sun Life Client Services at 800-247-6875 if you want to exercise conversion options or if you have any questions or require further information about this coverage.

    Please contact Manulife at gromail@manulife.com or 888-727-7766 for details regarding transferring your Group Retirement Savings Plan (RRSP) and your Non-registered Savings Plan (NRSP) or any other plans you hold for your retirement savings.

Stock Options

Any unvested options that you received under the Company’s Equity Incentive Plan will be cancelled on the End Date, October 31, 2022.

You have the right to exercise your vested options for a period of 90 days post termination, after which time your vested options will be cancelled. Please direct any inquiries regarding stock options to securities@auriniapharma.com.

WITHOUT PREJUDICE SEVERANCE OFFER
As the Company did not wish to terminate your employment, and your employment is coming to an end only by mutual agreement, the Company has no legal obligation to provide you with any termination notice entitlements under statute, contract, or otherwise. However, on the condition that you:
    Remain with the Company and continue to perform all of your assigned duties and responsibilities to the best of your ability until the end of the Working Notice Period;
    Resign any directorship or office held in the Company, or any subsidiary or affiliated companies of the Company, effective as of the End Date;
    Sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and return it to us within two (2) business days after the End Date; and
    Keep the terms of the offer confidential,
the Company is prepared to offer you a severance package on the following terms, in full and final satisfaction of all claims you may have against the Company and any affiliated company:
a)    The Company will pay to you a lump-sum payment of $899,688.00 CAD, less applicable statutory deductions and withholdings, which represents eighteen (18) months of your Base Salary (the “Severance Payment”), which will be paid on January 15, 2023, per your request;
b)    The Company will pay to you a lump-sum payment of $299,896.00 CAD, less applicable statutory deductions and withholdings, representing a target bonus payment equal to 50% of your Base Salary, which will be paid on March 15, 2023; and
c)    The Company will provide you with a 12-month career transition services package through Lee Hecht Harrison (LHH), which can be activated commencing on November 1, 2022 through to October 31, 2023.
For clarity, you will not be entitled to receive the severance package set out above if you terminate your employment for any reason, including if you resign, or if you have been terminated for just cause, prior to the end of the Working Notice Period.
As mentioned above, this without prejudice severance offer is made in full and final satisfaction of all claims you may have against the Company and its related entities. Accordingly, it is a condition of this offer that you sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and that you keep the terms of the offer confidential.
3


You may wish to obtain legal advice with respect to this offer.
If you wish to accept this offer, please sign and return a copy of this letter to us by no later than October 31, 2022. As set out above, you must sign and return the signed Release to us within two (2) business days after the End Date.
If you have any questions, please feel free to contact me.
Yours truly,

Aurinia Pharmaceuticals Inc.
Per:
/s/_Max Donley_________________________
Max Donley    
Executive VP, Operations & Strategy



4


ACKNOWLEDGEMENT AND ACCEPTANCE

I have read and understand the terms of this letter and the enclosed Release and confirm that I voluntarily accept the terms offered above in full and final satisfaction of all claims which I might have against Aurinia Pharmaceuticals Inc. and its related entities, including but not limited to those relating to or arising out of my employment with Aurinia Pharmaceuticals Inc. or the cessation of my employment. I acknowledge that I have been given the opportunity to obtain independent legal advice with respect to this offer, and that I am accepting it freely, voluntarily, and without duress.


Accepted: _/s/ Neil Solomons____________ Date: _October 20, 2022_____________________
    Neil Solomons

5


RELEASE
Neil Solomons (the “Employee”) for the consideration set out in the attached letter dated October 20, 2022 (the “Letter”), and for other good and valuable consideration, does, to the fullest extent permitted by law, forever release and forever discharge Aurinia Pharmaceuticals Inc. and Aurinia Pharma U.S. Inc., together with their affiliates, subsidiaries, directors, officers, employees, agents, owners and shareholders (collectively the “Company”) from any and all manners of actions, causes of actions, suits, contracts, claims, complaints, damages, costs and expenses of any nature or kind whatsoever known or unknown whether in law (including the common law) or in equity or pursuant to statute, which, as against the Company, the Employee has ever had or now has by reason of or arising out of any cause, matter or thing whatsoever occurring or existing up to the date of execution of this Release and, without limiting the generality of the foregoing, any matter, cause, or thing relating to or arising out of the Employee’s employment with the Company, the Employee’s contract of employment with the Company, or the cessation of Employee’s employment with the Company, and any other claim for damages, notice, payment in lieu of notice, wrongful dismissal, severance pay, loss of benefits including life insurance and long term and short term disability insurance, pension issues, bonus (pro-rated or otherwise), profit sharing, stock distribution, stock options or stock purchase rights, overtime pay, commissions, vacation pay, earned time off, or any claims under the British Columbia Employment Standards Act or the British Columbia Human Rights Code.
The Employee acknowledges that, upon receipt of the payments set out in the Letter, he/she will have received all payments and amounts owing to him/her under the British Columbia Employment Standards Act and that, to the fullest extent permitted by law, the payments made to him/her in the Letter are in full and final satisfaction of any further entitlements he/she may have pursuant to the British Columbia Employment Standards Act.
The Employee acknowledges that he/she has not be subjected to any form of discrimination or prohibited action whatsoever and hereby represents and warrants that he/she has not commenced any complaint and undertakes not to commence any complaint under the British Columbia Human Rights Code or Workers Compensation Act.
The Employee acknowledges and agrees that the consideration set out in the Letter includes full compensation and consideration for loss of employment benefits and that all of his/her employment benefits will cease as set out in the Letter. The Employee fully accepts sole responsibility to replace those benefits that he/she wishes to continue and to exercise conversion privileges where applicable with respect to benefits at his/her own cost. In the event that the Employee becomes disabled, he/she covenants not to sue the Company for insurance or other benefits, or for loss of benefits. The Employee hereby releases the Company from any and further obligations or liabilities arising from his/her employment benefits and the loss of such benefits.
The Employee covenants and undertakes not to defame, disparage or demean the Company, or any of its affiliates, subsidiaries, employees, officers, directors or agents, or any of its products or services, to any third party, in any manner whatsoever, including through social media.
This Release is binding upon and enures to the benefit of the Employee’s heirs, executors, administrators, assigns, committees and trustees.
This Release is binding upon and enures to the benefit of the Company’s affiliates, subsidiaries, directors, officers, employees, agents, predecessors, successors, assigns, liquidators, receivers, receiver managers, trustees, owners and shareholders.
In the event withholdings have not been deducted which should have been deducted, the Employee shall indemnify and save harmless the Company from any resulting liabilities, obligations, and costs regarding any claims which Canada Revenue Agency or Employment Insurance Commission may make upon the Company pursuant to the Income Tax Act (Canada), Employment Insurance Act (Canada), and/or the Canada Pension Plan, as such legislation or plans may be amended from time to
6


time, with respect to any payments made or benefits provided to or on behalf of the Employee or in respect of any Canada Pension Plan or Employment Insurance benefits or contributions.
The Employee acknowledges that the facts in respect of which this Release is made may prove to be other than or different from the facts in that connection now known or believed by the Employee to be true. The Employee accepts and assumes the risk of the facts being different and agrees that this Release shall be in all respects enforceable and not subject to termination, rescission, or variation by discovery of any differences in facts.
The Employee agrees not to make claim or take proceedings (including, but not limited to, any cross-claims, counter-claims, third party claims, actions or applications) against any other person or corporation that might claim contribution or indemnity under the provisions of any statute or otherwise against the Company.
        The Employee agrees to keep the terms of the Letter and this Release strictly confidential and will not disclose any information with respect to the Letter or this Release to anyone with the exception of his/her spouse and his/her legal or financial advisors, unless compelled to do so by law or court order.
The Employee acknowledges that this Release has been executed voluntarily after having had the opportunity to receive legal advice.
This Release is given voluntarily for the purposes of making a full and final settlement of all of the Employee’s claims whatsoever arising against the Company. This Release and the Letter are not to be construed or considered as an admission of liability by the Company.
In the event that any paragraph or portion thereof of this Release shall be invalid or unenforceable, for any reason whatsoever, then such invalid or unenforceable paragraph or portion shall be severed from the remainder of this Release, provided that it does not render the remainder of the Release unenforceable.
The Employee understands and agrees that this Release and the Letter contains the entire agreement between the Company and the Employee and that the terms of this Release are contractual and not recitals.
This Release shall be governed by the laws of the Province of British Columbia, Canada and the Employee hereby submits to the exclusive jurisdiction of the courts and tribunals of that province, as applicable.
Executed copies of this Release may be exchanged by facsimile or electronically via PDF format. Each facsimile or PDF copy so executed and exchanged will be deemed an original.
Dated at Victoria (city), the 20th day of October , 2022.




/s/ Neil Solomons    
Neil Solomons


7



8

 EX-10.26 4 exhibit1026separationagree.htm EX-10.26 Document
Exhibit 10.26
image_01.jpg

PERSONAL AND CONFIDENTIAL


October 20, 2022

Robert B. Huizinga
[redacted]

Dear Rob:
Re: End of Employment with Aurinia Pharmaceuticals Inc. (the “Company”)
Further to our recent discussions, as you are aware, the Company wished for you to assume the role of Senior Vice President, Medical Affairs, pursuant to your current terms and conditions of employment (including with respect to compensation and benefits). We view the position of Senior Vice President, Medical Affairs, as comparable to your current role of Executive Vice President, Research, and, in any event, as set out in your employment agreement with the Company dated October 1, 2018 (the “Employment Agreement”), the Company may vary or add to your position, duties and functions from time to time. However, we understand that this is not an arrangement you wish to accept, and that you wish to end your employment.
As such, this letter confirms that you and the Company have mutually agreed that your employment with the Company will come to an end, effective October 31, 2022 (the “End Date”). This letter also sets forth details regarding the end of your employment and makes a without prejudice severance offer in exchange for a full and final Release in favour of the Company.
GENERAL
Working Notice and Statutory Payments
From now until the End Date (the “Working Notice Period”), you will be expected to perform your assigned duties and responsibilities to the best of your ability, and you will continue to receive your usual compensation and benefits, less applicable deductions and withholdings.
Following the End Date, the balance of all outstanding wages, including any accrued and unused vacation pay, will be paid to you in a lump sum. Your accrued and unused vacation entitlements will be paid out on October 31, 2022, and are as follows:
    Accrued (unused) vacation = 149.83 hours ($41,643.62 CAD) (provided no vacation is taken between now and the End Date)
    Grandfathered vacation = 770.54 hours ($163,633.52 CAD)
These amounts are subject to the usual deductions, and you will be paid these amounts regardless of whether you accept the without prejudice severance offer detailed below.
Note that, in the event that you are terminated for just cause or resign from your employment prior to the end of the Working Notice Period, all payments and benefits will cease and you will not receive any further compensation or pay in lieu, except as may be minimally required pursuant to the British Columbia Employment Standards Act.
Record of Employment
Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii)
would be competitively harmful if publicly disclosed.


After the end of the Working Notice Period, your Record of Employment will be submitted electronically to Service Canada, which you will be able to access online on the Service Canada website. We encourage you to visit the Service Canada website at: https://www.canada.ca/en/services/benefits/ei.html to familiarize yourself with the available Employment Insurance (EI) application process and support services offered by the Canadian Government.
Outstanding Business Expenses
After the end of the Working Notice Period, outstanding unreimbursed business expenses will be paid within the Company’s normal policies for expense reimbursement following submission of the expense report.
Return of Company Property
On or before the End Date, please return to the Company all its property, including, but not limited to, building access card, laptop, iPad, passwords, computer usernames, voicemail code, phone cards, company credit card, keys, internal policies, and other confidential business information and documents, and any other property belonging to the Company. Please also destroy or delete all tangible or electronic copies of any such property after returning it to the Company.
Confidentiality and Other Continuing Obligations
We wish to remind you that, despite the cessation of your employment with the Company, you continue to be bound by:

    The Confidentiality and Work Product Ownership Agreement attached as Schedule B to the Employment Agreement;

    All restrictive covenants contained in the Employment Agreement, including paragraph 24 (Restrictive Covenant) of the Employment Agreement; and

    All fiduciary duties that arise from your employment.

The Company expects you to comply with these obligations, which survive the cessation of your employment.




Benefits

Subject to provider approval and the terms and conditions of the applicable plans, the Company will maintain your Medical, Dental, and Vision benefits until the earlier of:
i.     the date you obtain replacement benefits; or
ii.     twelve (12) months from the End Date,
after which time you will be responsible for obtaining your own replacement benefits.

Coverage for your Short Term & Long-Term Disability, Life Insurance, AD&D, Group Retirement Savings Plan, and all other benefits other than Medical, Dental, and Vision benefits, will terminate as of the End Date, October 31, 2022, and you will be responsible for obtaining your own replacement benefits.

There may be conversion options available to you through Sun Life that are subject to strict time limitations (e.g., within 31 days of your coverage termination date):

2


    Please call Sun Life Client Services at 800-247-6875 if you want to exercise conversion options or if you have any questions or require further information about this coverage.

    Please contact Manulife at gromail@manulife.com or 888-727-7766 for details regarding transferring your Group Retirement Savings Plan (RRSP) and your Non-registered Savings Plan (NRSP) or any other plans you hold for your retirement savings.

Stock Options

Any unvested options that you received under the Company’s Equity Incentive Plan will be cancelled on the End Date, October 31, 2022.

You have the right to exercise your vested options for a period of 90 days post termination, after which time your vested options will be cancelled. Please direct any inquiries regarding stock options to securities@auriniapharma.com.

WITHOUT PREJUDICE SEVERANCE OFFER

As the Company did not wish to terminate your employment, and your employment is coming to an end only by mutual agreement, the Company has no legal obligation to provide you with any termination notice entitlements under statute, contract, or otherwise. However, on the condition that you:

    Remain with the Company and continue to perform all of your assigned duties and responsibilities to the best of your ability until the end of the Working Notice Period;

    Resign any directorship or office held in the Company, or any subsidiary or affiliated companies of the Company, effective as of the End Date;

    Sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and return it to us within two (2) business days after the End Date; and

    Keep the terms of the offer confidential,

the Company is prepared to offer you a severance package on the following terms, in full and final satisfaction of all claims you may have against the Company and any affiliated company:

a)    The Company will pay to you a lump-sum payment of $740,921.94 CAD, less applicable statutory deductions and withholdings, which represents eighteen (18) months of your annualized Base Salary (the “Severance Payment”), which will be paid on January 15, 2023, per your request;

b)    The Company will pay to you a lump-sum payment of $246,974.00 CAD, less applicable statutory deductions and withholdings, representing a target bonus payment equal to 50% of your Base Salary, which will be paid on March 15, 2023;
c)    You will continue to be eligible to receive the Retention Incentive set out at Section 8 of the Employment Agreement; and
d)    The Company will provide you with a 12-month career transition services package through Lee Hecht Harrison (LHH), which can be activated commencing on November 1, 2022 through to October 31, 2023.
For clarity, you will not be entitled to receive the severance package set out above if you terminate your employment for any reason, including if you resign, or if you have been terminated for just cause, prior to the end of the Working Notice Period.
As mentioned above, this without prejudice severance offer is made in full and final satisfaction of all claims you may have against the Company and its related entities. Accordingly, it is a condition of this
3


offer that you sign the attached Release on or after the End Date (i.e., after the end of the Working Notice Period), and that you keep the terms of the offer confidential.
You may wish to obtain legal advice with respect to this offer.
If you wish to accept this offer, please sign and return a copy of this letter to us by no later than October 31, 2022. As set out above, you must sign and return the signed Release to us within two (2) business days after the End Date.
If you have any questions, please feel free to contact me.
Yours truly,

Aurinia Pharmaceuticals Inc.
Per:
/s/ Max Donley_________________
Max Donley    
Executive VP, Operations & Strategy



ACKNOWLEDGEMENT AND ACCEPTANCE

I have read and understand the terms of this letter and the enclosed Release and confirm that I voluntarily accept the terms offered above in full and final satisfaction of all claims which I might have against Aurinia Pharmaceuticals Inc. and its related entities, including but not limited to those relating to or arising out of my employment with Aurinia Pharmaceuticals Inc. or the cessation of my employment. I acknowledge that I have been given the opportunity to obtain independent legal advice with respect to this offer, and that I am accepting it freely, voluntarily, and without duress.


Accepted: _/s/ Robert B. Huizinga_______________ Date: _October 20, 2022_______________
    Robert B. Huizinga

4


RELEASE
Robert B. Huizinga (the “Employee”) for the consideration set out in the attached letter dated October 20, 2022 (the “Letter”), and for other good and valuable consideration, does, to the fullest extent permitted by law, forever release and forever discharge Aurinia Pharmaceuticals Inc. and Aurinia Pharma U.S. Inc., together with their affiliates, subsidiaries, directors, officers, employees, agents, owners and shareholders (collectively the “Company”) from any and all manners of actions, causes of actions, suits, contracts, claims, complaints, damages, costs and expenses of any nature or kind whatsoever known or unknown whether in law (including the common law) or in equity or pursuant to statute, which, as against the Company, the Employee has ever had or now has by reason of or arising out of any cause, matter or thing whatsoever occurring or existing up to the date of execution of this Release and, without limiting the generality of the foregoing, any matter, cause, or thing relating to or arising out of the Employee’s employment with the Company, the Employee’s contract of employment with the Company, or the cessation of Employee’s employment with the Company, and any other claim for damages, notice, payment in lieu of notice, wrongful dismissal, severance pay, loss of benefits including life insurance and long term and short term disability insurance, pension issues, bonus (pro-rated or otherwise), profit sharing, stock distribution, stock options or stock purchase rights, overtime pay, commissions, vacation pay, earned time off, or any claims under the British Columbia Employment Standards Act or the British Columbia Human Rights Code.
The Employee acknowledges that, upon receipt of the payments set out in the Letter, he/she will have received all payments and amounts owing to him/her under the British Columbia Employment Standards Act and that, to the fullest extent permitted by law, the payments made to him/her in the Letter are in full and final satisfaction of any further entitlements he/she may have pursuant to the British Columbia Employment Standards Act.
The Employee acknowledges that he/she has not be subjected to any form of discrimination or prohibited action whatsoever and hereby represents and warrants that he/she has not commenced any complaint and undertakes not to commence any complaint under the British Columbia Human Rights Code or Workers Compensation Act.
The Employee acknowledges and agrees that the consideration set out in the Letter includes full compensation and consideration for loss of employment benefits and that all of his/her employment benefits will cease as set out in the Letter. The Employee fully accepts sole responsibility to replace those benefits that he/she wishes to continue and to exercise conversion privileges where applicable with respect to benefits at his/her own cost. In the event that the Employee becomes disabled, he/she covenants not to sue the Company for insurance or other benefits, or for loss of benefits. The Employee hereby releases the Company from any and further obligations or liabilities arising from his/her employment benefits and the loss of such benefits.
The Employee covenants and undertakes not to defame, disparage or demean the Company, or any of its affiliates, subsidiaries, employees, officers, directors or agents, or any of its products or services, to any third party, in any manner whatsoever, including through social media.
This Release is binding upon and enures to the benefit of the Employee’s heirs, executors, administrators, assigns, committees and trustees.
This Release is binding upon and enures to the benefit of the Company’s affiliates, subsidiaries, directors, officers, employees, agents, predecessors, successors, assigns, liquidators, receivers, receiver managers, trustees, owners and shareholders.
In the event withholdings have not been deducted which should have been deducted, the Employee shall indemnify and save harmless the Company from any resulting liabilities, obligations, and costs regarding any claims which Canada Revenue Agency or Employment Insurance Commission may make upon the Company pursuant to the Income Tax Act (Canada), Employment Insurance Act (Canada), and/or the Canada Pension Plan, as such legislation or plans may be amended from time to
5


time, with respect to any payments made or benefits provided to or on behalf of the Employee or in respect of any Canada Pension Plan or Employment Insurance benefits or contributions.
The Employee acknowledges that the facts in respect of which this Release is made may prove to be other than or different from the facts in that connection now known or believed by the Employee to be true. The Employee accepts and assumes the risk of the facts being different and agrees that this Release shall be in all respects enforceable and not subject to termination, rescission, or variation by discovery of any differences in facts.
The Employee agrees not to make claim or take proceedings (including, but not limited to, any cross-claims, counter-claims, third party claims, actions or applications) against any other person or corporation that might claim contribution or indemnity under the provisions of any statute or otherwise against the Company.
        The Employee agrees to keep the terms of the Letter and this Release strictly confidential and will not disclose any information with respect to the Letter or this Release to anyone with the exception of his/her spouse and his/her legal or financial advisors, unless compelled to do so by law or court order.
The Employee acknowledges that this Release has been executed voluntarily after having had the opportunity to receive legal advice.
This Release is given voluntarily for the purposes of making a full and final settlement of all of the Employee’s claims whatsoever arising against the Company. This Release and the Letter are not to be construed or considered as an admission of liability by the Company.
In the event that any paragraph or portion thereof of this Release shall be invalid or unenforceable, for any reason whatsoever, then such invalid or unenforceable paragraph or portion shall be severed from the remainder of this Release, provided that it does not render the remainder of the Release unenforceable.
The Employee understands and agrees that this Release and the Letter contains the entire agreement between the Company and the Employee and that the terms of this Release are contractual and not recitals.
This Release shall be governed by the laws of the Province of British Columbia, Canada and the Employee hereby submits to the exclusive jurisdiction of the courts and tribunals of that province, as applicable.
Executed copies of this Release may be exchanged by facsimile or electronically via PDF format. Each facsimile or PDF copy so executed and exchanged will be deemed an original.
Dated at Victoria (city), the 20th day of October, 2022.




/s/ Robert B. Huizinga        
Robert B. Huizinga


6



7

 EX-31.1 5 auph-2022q3exx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 2, 2022By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 6 auph-2022q3exx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 2, 2022By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 7 auph-2022q3exx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 2, 2022By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 8 auph-2022q3exx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 2, 2022By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 9 auph-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - License and Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Lease Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - License and Collaboration Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 auph-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 auph-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 auph-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Related Party Transactions [Abstract] Upfront payments received Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Entity Address, Postal Zip Code Entity Address, Postal Zip Code Tiered royalty percentages on future sales Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Area of property (in sqft) Area of Real Estate Property Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Property, Plant and Equipment [Abstract] Unrealized gain (loss) on available-for-sale securities, net of tax of nil Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Property, plant and equipment, gross Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Cash received for interest Proceeds from Interest Received Cash flows used in investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Financial Instruments [Domain] Financial Instruments [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation and amortization Depreciation Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Incremental borrowing rate Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Proceeds from investments Proceeds from Sale and Maturity of Marketable Securities Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Commercial accruals Commercial Related Accruals, Current Commercial Related Accruals, Current Other, net Other Noncash Income (Expense) Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Annualized volatility(as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Prepaid insurance Prepaid Insurance Equity Component [Domain] Equity Component [Domain] Total financial assets Assets, Fair Value Disclosure Lease Obligations Lessee, Operating Leases [Text Block] Related Party [Domain] Related Party [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Available-for-sale debt securities Debt Securities, Available-for-Sale Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Number of operating segments Number of Operating Segments Plan Name [Domain] Plan Name [Domain] Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Outstanding Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Employee Stock Employee Stock [Member] Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current Purchase period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Proceeds from tenant improvements Payments for (Proceeds from) Tenant Allowance Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Number of purchase periods Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods Weighted average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and Equipment, net Property, Plant and Equipment [Table Text Block] Capitalized under inventories Inventories [Member] Product Revenues Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Triggered milestone, payments Research And Development Arrangement, Contract To Perform, Milestone Payments Research And Development Arrangement, Contract To Perform, Milestone Payments Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Unrealized Losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Number of new employees Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Financial assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) Outstanding, Weighted average exercise price - End of Period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Product and Service [Domain] Product and Service [Domain] Cash flows used in operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Purchase of non-current assets Payments to Acquire Other Productive Assets 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Expected payments prior to commencement of lease Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease Financial Instrument [Axis] Financial Instrument [Axis] Proceeds from exercise of warrants Proceeds from Warrant Exercises Affiliated Shareholder Affiliated Entity [Member] Revenue Benchmark Revenue Benchmark [Member] Document Period End Date Document Period End Date Total assets Assets Earnings Per Share [Abstract] Accounts receivable, net Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Unrealized gain on available-for-sale securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Unvested performance awards Performance Shares [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Employee accruals Employee-related Liabilities, Current Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Milestone Payment Milestone Payment [Member] Milestone Payment Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Derivative, average remaining maturity Derivative, Average Remaining Maturity Net Loss per Common Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Schedule of Share-based Payment Award Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Lease liabilities Increase (Decrease) in Operating Lease Liability Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Unrecognized share-based compensation expense weighted average recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Potential regulatory milestone revenue Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Computer equipment Computer Equipment [Member] Upfront license payment Payments to Acquire Other Investments Finished goods inventories Inventory, Finished Goods, Gross Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Investments Marketable Securities [Table Text Block] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Events Subsequent Events [Text Block] Patents Patents [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Operating expenses Operating Expenses [Abstract] Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value ($ per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Inventory write-down Inventory Write-down Specialty Pharmacy One Specialty Pharmacy One [Member] Specialty Pharmacy One Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Intangible Assets Intangible Assets Disclosure [Text Block] ILJIN ILJIN [Member] ILJIN Research and development Research and Development Expense Title of Individual [Axis] Title of Individual [Axis] Marketable Securities [Line Items] Marketable Securities [Line Items] Restricted cash Restricted Cash and Cash Equivalents Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Unvested restricted units Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Inducement Stock Option Share-Based Payment Arrangement, Inducement Option [Member] Share-Based Payment Arrangement, Inducement Option Milestone Achievement Milestone Achievement [Member] Milestone Achievement Concentration risk (as percent) Concentration Risk, Percentage Subsequent Events [Abstract] Number of additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Cash, Cash Equivalents, Restricted Cash and Short-Term Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Due to related parties Due to Related Parties Finished goods Inventory, Finished Goods, Net of Reserves Amortization of intangible assets Amortization of Intangible Assets Basic loss per share ($ per share) Basic loss per share ($ per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total shareholders' equity Balance Balance Stockholders' Equity Attributable to Parent Prepaid expenses Prepaid expenses Prepaid Expense, Current Performance share forfeited, Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Otuska Otuska Pharmaceutical Co., Ltd. [Member] Otuska Pharmaceutical Co., Ltd. Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Net changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Accumulated Deficit Retained Earnings [Member] Unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common Shares Common Stock [Member] Lease, Cost Lease, Cost [Table Text Block] Number of extension options Lessee, Operating Lease, Number of Extension Options Lessee, Operating Lease, Number of Extension Options Statement [Table] Statement [Table] Short-term investments Debt Securities, Current Performance shares vested, Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Lease extension term Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report New Employees New Employees [Member] New Employees Total cash, cash equivalents, restricted cash and short-term investments Total cash, cash equivalents, restricted cash and short-term investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments Furniture Furniture and Fixtures [Member] Current assets Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchase of investments Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Lease termination option term Lessee, Operating Lease, Lease Termination Term Lessee, Operating Lease, Lease Termination Term Interest income Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Statement [Line Items] Statement [Line Items] Capital expenditure payments Finance Lease, Principal Payments Payments for capital improvements Payments for Capital Improvements Outstanding - Beginning of Period (in shares) Outstanding - End of Period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Gross Carrying Value Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Product revenue, net Product Sales Product [Member] Right-of-use assets, net Operating Lease, Right-of-Use Asset Treasury bill US Treasury Bill Securities [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Total held to maturity securities at amortized cost Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current Amended and Restated Equity Incentive Plan Amended and Restated Equity Incentive Plan [Member] Amended and Restated Equity Incentive Plan Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets Additional Cash Flow Elements, Summations [Abstract] Upfront license fee Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventories, net Increase (Decrease) in Inventories Recently adopted accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Common stock, outstanding (shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Service Revenue Service [Member] Other Current Liabilities Other Current Liabilities [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Treasury bond US Treasury Bond Securities [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Income tax expense Income tax (benefit) expense Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Riptide Bioscience, Inc. Riptide Bioscience, Inc. [Member] Riptide Bioscience, Inc. Additional paid in capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Prepaid assets Prepaid Assets, Current Prepaid Assets, Current Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Inventories, net Schedule of Inventory, Current [Table Text Block] Expected life of options in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Granted, weighted average exercise price (in usd per share) Performance shares awards, weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Other (income) expense, net Other Operating Income (Expense), Net Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Proceeds from exercise of stock options and employee share purchase plan Proceeds from Stock Options Exercised Common stock, issued (shares) Common Stock, Shares, Issued Income Statement Location [Domain] Income Statement Location [Domain] License Agreement Terms License Agreement Terms [Member] Outside United States Outside United States [Member] Outside United States Amendment Flag Amendment Flag Remaining lease term Lessee, Operating Lease, Remaining Lease Term Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating lease costs Operating Lease, Cost Prepaid Expenses Prepaid Expenses [Text Block] Prepaid Expenses Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income (Loss), Net of Tax Issuance of common shares in conjunction with ESPP program Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Upfront lease payment Payments to Acquire Lease Receivables Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Other current liabilities Other Liabilities, Current Other non-current assets Other Assets, Noncurrent Accrued R&D projects Accrued Research, Current Accrued Research, Current Unrealized gains on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Lease term Lessee, Operating Lease, Term of Contract Issuance of common shares in conjunction with ESPP program (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of warrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Basis of presentation Basis of Accounting, Policy [Policy Text Block] LIABILITIES Liabilities [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Cash paid for amounts included in the measurement of lease liabilities Lease Obligation Incurred Office equipment Office Equipment [Member] Stock options Share-Based Payment Arrangement, Option [Member] Non-current assets Increase (Decrease) in Other Noncurrent Assets Title of Individual [Domain] Title of Individual [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Shares issued on exercise of stock options and vesting of performance awards and restricted stock units Stock Issued During Period, Value, Stock Options Exercised Shares forfeited/canceled (in shares) Performance shares forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Balance Sheet Location [Axis] Balance Sheet Location [Axis] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Non-current assets Assets, Noncurrent [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Restricted cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Income taxes payable Taxes Payable, Current Cash paid for taxes Income Taxes Paid, Net Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Entity Small Business Entity Small Business Revenue Revenues [Abstract] Acquired intellectual property and other intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Restricted cash Restricted Cash Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Internal-use software implementation costs Computer Software, Intangible Asset [Member] Number of shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Prepaid deposits Deposits Assets, Current Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Schedule of Performance Shares Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total cost of sales and operating expenses Costs and Expenses Payables and Accruals [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Total lease liabilities Total future minimum lease payments Operating Lease, Liability Share-based Compensation Share-Based Payment Arrangement [Policy Text Block] Officer Officer [Member] Minimum finance lease liability payments due Finance Lease, Liability, to be Paid Investments, Debt and Equity Securities [Abstract] Deferred Compensation and Other Non-current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block] Cash, cash equivalents and restricted cash Cash, Cash Equivalents And Restricted Cash [Member] Cash, Cash Equivalents And Restricted Cash Member Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Inventories, net Total inventories Inventory, Net Warrants Warrant [Member] Entity Filer Category Entity Filer Category Weighted-average common shares outstanding used in computation of basic loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic SHAREHOLDER’S EQUITY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] United States UNITED STATES Share-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 17) Commitments and Contingencies Security Exchange Name Security Exchange Name Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Yankee bond Yankee Bond [Member] Yankee Bond License and collaboration revenue License [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Corporate bond Short-Term Corporate Debt Securities [Member] Short-Term Corporate Debt Securities Unamortized expense Share-Based Payment Arrangement, Unamortized Expense Share-Based Payment Arrangement, Unamortized Expense Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Selling, general and administrative General and Administrative Expense [Member] Total revenue, net Revenues Revenue from Contract with Customer, Excluding Assessed Tax Corporate bond Corporate Bond Securities [Member] Exercise of warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Non-current liabilities Liabilities, Noncurrent [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Share-Based Payment Arrangement [Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Allocation of Share-Based Payments Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Work in process Inventory, Work in Process, Net of Reserves Estimated Fair Value Debt Securities, Held-to-Maturity, Fair Value License and Collaboration Agreement Revenue from Contract with Customer [Text Block] Cash and cash equivalents and investments Cash, Cash Equivalents and Debt Securities, Current Cash, Cash Equivalents and Debt Securities, Current Risk-free interest rate (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total liabilities and shareholders’ equity Liabilities and Equity Rockville, Maryland Rockville, Maryland [Member] Rockville, Maryland Related Party [Axis] Related Party [Axis] Interest receivable Interest Receivable Accounts receivable Increase (Decrease) in Receivables Organization, Consolidation and Presentation of Financial Statements [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Estimated forfeiture rate (as percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: lease imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted loss per share ($ per share) Diluted loss per share ($ per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Shared-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Acquired intellectual property and reacquired rights Intellectual Property [Member] Customer Concentration Risk Customer Concentration Risk [Member] Marketable Securities [Table] Marketable Securities [Table] Accounts receivable, net Accounts and Other Receivables, Net, Current Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Cost of sales Cost of Revenue Product and Service [Axis] Product and Service [Axis] Victoria, British Columbia Victoria, British Columbia [Member] Victoria, British Columbia Fair Value Disclosures [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Payments to related party Related Party Transaction, Amounts of Transaction Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Inventories, net Inventory Disclosure [Text Block] Subsequent Event [Table] Subsequent Event [Table] Performance shares vested (in shares) Performance shares vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventory Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Revenue from Contract with Customer [Abstract] Upfront license and milestone expense Acquired Upfront License Payment Acquired Upfront License Payment Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Weighted average exercise price $ Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Major Customers Concentration Risk, Credit Risk, Policy [Policy Text Block] Other accrued liabilities Other Accrued Liabilities, Current City Area Code City Area Code Selling, general and administrative General and Administrative Expense ASSETS Assets [Abstract] Additions to internal use-software implementation costs Payments for Software Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Schedule Of Prepaid Expenses And Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Supplemental disclosure of noncash transactions Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Fair value per common share option (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Future value of minimum lease payments of leases not yet commenced Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid Performance Share sand Restricted Stock Units (RSUs) Performance Share sand Restricted Stock Units (RSUs) [Member] Performance Share sand Restricted Stock Units (RSUs) Deferred compensation and other non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Research and development Research and Development Expense [Member] Receivable standard credit terms (in days) Accounts Receivable, Credit Term Accounts Receivable, Credit Term Schedule of Loss Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Initial recognition of operating lease right-of-use asset Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Customer [Domain] Customer [Domain] U.S. agency security U.S. Agency Security [Member] U.S. Agency Security EX-101.PRE 13 auph-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 image_0.jpg begin 644 image_0.jpg MB5!.1PT*&@H -24A$4@ 5$ !@" ( K1=:I B9DE$051X7NV= MAU<3>;3']W]X;]UWSBNK G8("46:7;$7[!7;VF@JHEA85Y&B(!T$>T%$Q+X6 M;* B*$5$K( *B H(H2;4!-Y-1N+D3LJD$G4^YQ[.D-R9^65FOK_?_=7YK:LG MZ*AXUU9P#W_*P,"@>W[#'^B>CB_%=;Z.=>L'--\^A+]C8�,?K6?/O'5W4[ M1]:[FU2[&C>XFS2=\1&VM6 G!@8&G:%7S;>7%=3N< #!5[D8@WUU,6Y:;](0 MMUK(J\>N# P,ND%_FN\H?UWG,TPB>(F![.M#YPOJJO .# P,.D!/FHC8&!0=OH0_."FO):7T=Y@O\N>__)'37E>&<&!@:M M\ELG_D3+")MJZ_8Y-7@H$OQWV0=,$=9^P8=@8�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end GRAPHIC 15 image_01.jpg begin 644 image_01.jpg MB5!.1PT*&@H -24A$4@ 5$ !@" ( K1=:I B9DE$051X7NV= MAU<3>;3']W]X;]UWSBNK G8("46:7;$7[!7;VF@JHEA85Y&B(!T$>T%$Q+X6 M;* B*$5$K( *B H(H2;4!-Y-1N+D3LJD$G4^YQ[.D-R9^65FOK_?_=7YK:LG MZ*AXUU9P#W_*P,"@>W[#'^B>CB_%=;Z.=>L'--\^A+]C8�,?K6?/O'5W4[ M1]:[FU2[&C>XFS2=\1&VM6 G!@8&G:%7S;>7%=3N< #!5[D8@WUU,6Y:;](0 MMUK(J\>N# P,ND%_FN\H?UWG,TPB>(F![.M#YPOJJO .# P,.D!/FHC8&!0=OH0_."FO):7T=Y@O\N>__)'37E>&<&!@:M M\ELG_D3+")MJZ_8Y-7@H$OQWV0=,$=9^P8=@8�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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
COVER - shares
 9 Months Ended
Sep. 30, 2022
Nov. 02, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One #1203-4464 Markham Street  
Entity Tax Identification Number 98-1231763  
Entity Address, City or Town Victoria  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V8Z 7X8  
City Area Code (250)  
Local Phone Number 744-2487  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   142,109,703
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets    
Cash, cash equivalents and restricted cash $ 86,052 $ 231,900
Short-term investments 290,592 234,178
Accounts receivable, net 41,771 15,414
Inventories, net 25,320 19,326
Prepaid expenses 12,159 11,710
Other current assets 3,808 796
Total current assets 459,702 513,324
Non-current assets    
Other non-current assets 13,049 11,838
Property and equipment, net 3,758 4,418
Acquired intellectual property and other intangible assets, net 6,839 8,404
Right-of-use assets, net 4,945 5,383
Total assets 488,293 543,367
Current liabilities    
Accounts payable and accrued liabilities 40,123 34,947
Other current liabilities 724 4,640
Operating lease liabilities 918 1,059
Total current liabilities 41,765 40,646
Non-current liabilities    
Deferred compensation and other non-current liabilities 15,833 15,950
Operating lease liabilities 7,270 7,680
Total liabilities 64,868 64,276
Commitments and contingencies (Note 17)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 1,184,020 1,177,051
Additional paid-in capital 79,188 59,014
Accumulated other comprehensive loss (1,527) (852)
Accumulated deficit (838,256) (756,122)
Total shareholders' equity 423,425 479,091
Total liabilities and shareholders’ equity $ 488,293 $ 543,367
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common stock, par value ($ per share) $ 0 $ 0
Common stock, issued (shares) 142,110,000 141,600,000
Common stock, outstanding (shares) 142,110,000 141,600,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue        
Total revenue, net $ 55,779 $ 14,667 $ 105,595 $ 22,201
Operating expenses        
Cost of sales 2,447 254 4,302 610
Selling, general and administrative 52,169 44,645 148,898 128,772
Research and development 10,973 20,066 35,118 39,990
Other (income) expense, net (311) 55 647 859
Total cost of sales and operating expenses 65,278 65,020 188,965 170,231
Loss from operations (9,499) (50,353) (83,370) (148,030)
Interest income 1,464 106 2,209 420
Net loss before income taxes (8,035) (50,247) (81,161) (147,610)
Income tax expense 954 8 973 34
Net loss (8,989) (50,255) (82,134) (147,644)
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities, net of tax of nil 326 (2) (675) 11
Comprehensive loss $ (8,663) $ (50,257) $ (82,809) $ (147,633)
Basic loss per share ($ per share) $ (0.06) $ (0.39) $ (0.58) $ (1.15)
Diluted loss per share ($ per share) $ (0.06) $ (0.39) $ (0.58) $ (1.15)
Weighted-average common shares outstanding used in computation of basic loss per share (in shares) 141,856 128,443 141,831 128,084
Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) 141,856 128,443 141,831 128,084
Product revenue, net        
Revenue        
Total revenue, net $ 25,502 $ 14,638 $ 75,142 $ 22,113
License and collaboration revenue        
Revenue        
Total revenue, net $ 30,277 $ 29 $ 30,453 $ 88
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Unrealized gain on available-for-sale securities, tax $ 0 $ 0 $ 0 $ 0
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance (in shares) at Dec. 31, 2020   126,725,000      
Balance at Dec. 31, 2020 $ 407,750 $ 944,328 $ 39,383 $ (805) $ (575,156)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   2,324,000      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 15,352 $ 22,097 (6,745)    
Exercise of warrants (in shares)   521,000      
Exercise of warrants 37 $ 734 (697)    
Shared-based compensation 22,666   22,666    
Unrealized gain (loss) on available-for-sale securities 11     11  
Net loss (147,644)       (147,644)
Balance (in shares) at Sep. 30, 2021   129,570,000      
Balance at Sep. 30, 2021 298,172 $ 967,159 54,607 (794) (722,800)
Balance (in shares) at Jun. 30, 2021   128,396,000      
Balance at Jun. 30, 2021 332,257 $ 954,572 51,022 (792) (672,545)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   1,172,000      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 9,074 $ 12,579 (3,505)    
Exercise of warrants (in shares)   2,000      
Exercise of warrants 6 $ 8 (2)    
Shared-based compensation 7,092   7,092    
Unrealized gain (loss) on available-for-sale securities (2)     (2)  
Net loss (50,255)       (50,255)
Balance (in shares) at Sep. 30, 2021   129,570,000      
Balance at Sep. 30, 2021 $ 298,172 $ 967,159 54,607 (794) (722,800)
Balance (in shares) at Dec. 31, 2021 141,600,000 141,600,000      
Balance at Dec. 31, 2021 $ 479,091 $ 1,177,051 59,014 (852) (756,122)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares) 77,000 383,000      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units $ 522 $ 5,064 (4,542)    
Issuance of common shares in conjunction with ESPP program (in shares)   127,000      
Issuance of common shares in conjunction with ESPP program 1,223 $ 1,905 (682)    
Shared-based compensation 25,398   25,398    
Unrealized gain (loss) on available-for-sale securities (675)     (675)  
Net loss $ (82,134)       (82,134)
Balance (in shares) at Sep. 30, 2022 142,110,000 142,110,000      
Balance at Sep. 30, 2022 $ 423,425 $ 1,184,020 79,188 (1,527) (838,256)
Balance (in shares) at Jun. 30, 2022   141,892,000      
Balance at Jun. 30, 2022 423,768 $ 1,180,884 74,004 (1,853) (829,267)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   218,000      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 0 $ 3,136 (3,136)    
Shared-based compensation 8,320   8,320    
Unrealized gain (loss) on available-for-sale securities 326     326  
Net loss $ (8,989)       (8,989)
Balance (in shares) at Sep. 30, 2022 142,110,000 142,110,000      
Balance at Sep. 30, 2022 $ 423,425 $ 1,184,020 $ 79,188 $ (1,527) $ (838,256)
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows used in operating activities:    
Net loss $ (82,134) $ (147,644)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 2,487 2,030
Upfront license and milestone expense 0 10,000
Share-based compensation expense 25,398 22,666
Inventory write-down 2,464 0
Other, net 587 1,005
Net changes in operating assets and liabilities    
Accounts receivable (26,356) (9,815)
Inventories, net (8,458) (5,366)
Prepaid expenses and other current assets (3,461) (6,541)
Non-current assets (830) 247
Accounts payable, accrued and other liabilities 875 1,149
Lease liabilities (551) 499
Net cash used in operating activities (89,979) (131,770)
Cash flows used in investing activities:    
Purchase of investments (403,184) (342,831)
Proceeds from investments 346,109 263,752
Upfront lease payment (381) (11,838)
Upfront license payment 0 (6,000)
Purchase of non-current assets (158) (268)
Additions to internal use-software implementation costs 0 (1,198)
Net cash used in investing activities (57,614) (98,383)
Cash flows from financing activities    
Proceeds from exercise of stock options and employee share purchase plan 1,745 15,353
Proceeds from exercise of warrants 0 37
Cash provided by financing activities 1,745 15,390
Net decrease in cash, cash equivalents and restricted cash (145,848) (214,763)
Cash, cash equivalents and restricted cash, beginning of period 231,900 272,350
Cash, cash equivalents and restricted cash, end of period 86,052 57,587
Supplemental cash flow information    
Cash received for interest 1,705 671
Cash paid for taxes (779) (236)
Cash paid for amounts included in the measurement of lease liabilities (897) (195)
Supplemental disclosure of noncash transactions    
Initial recognition of operating lease right-of-use asset 0 419
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets    
Cash, cash equivalents 85,341 57,587
Restricted cash 711 0
Total cash, cash equivalents and restricted cash $ 86,052 $ 57,587
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Description of Business
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.
On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.
On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $376.6 million as of September 30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.
Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
Restricted cash: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7 million and $0.3 million as of September 30, 2022 and December 31, 2021, respectively.
Major Customers: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September 30, 2022 and 74% for the nine months ended September 30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September 30, 2022 of the Company's total revenues.
In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.
Milestone Payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be
included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. As of September 30, 2022, we recognized $30.0 million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September 30, 2022 and December 31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September 30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September 30, 2022 and as of December 31, 2021.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.
Recently adopted accounting pronouncements
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.
In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the
Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:
September 30, 2022
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security— 4,904 — 4,904 
Corporate bond— 98,068 — 98,068 
Commercial paper112,633 — — 112,633 
Treasury bill— 26,704 — 26,704 
Treasury bond— 44,553 — 44,553 
Yankee bond— 3,730 — 3,730 
Total financial assets$198,685 $177,959 $— $376,644 
December 31, 2021
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit— 3,140 — 3,140 
Corporate bond— 21,820 — 21,820 
Commercial paper206,724 — — 206,724 
Treasury bill— 2,494 — 2,494 
Total financial assets$438,624 $27,454 $— $466,078 
The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2022, and December 31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for 7 months and 8 months, respectively. These investments have an overall rating of A-1, or higher, by Moody’s, Standard & Poor’s and Fitch.
No credit loss allowance was recorded as of September 30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, “Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments Cash, Cash Equivalents, Restricted Cash and Short-Term Investments
As of September 30, 2022 and December 31, 2021, the Company had $376.6 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September 30, 2022, $376.6 million were available-for-sale debt securities which are carried at fair market value. As of December 31, 2021, $446.9 million were classified as available-for-sale and $19.2 million were held-to-maturity.
September 30, 2022
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security4,900 4 — 4,904 
Corporate bond98,448 — (380)98,068 
Commercial paper112,833 — (200)112,633 
Treasury bill26,721 — (17)26,704 
Treasury bond44,670 — (117)44,553 
Yankee bond3,742 — (12)3,730 
Total cash, cash equivalents, restricted cash and short-term investments$377,366 $4 $(726)$376,644 
December 31, 2021
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit3,144 — (4)3,140 
Corporate bond2,592 — (1)2,591 
Commercial paper206,764 — (40)206,724 
Treasury bill2,497 — (2)2,495 
Total$446,897 $— $(47)$446,850 
Total held to maturity securities at amortized cost19,228 
Total cash, cash equivalents, restricted cash and short-term investments$466,078 

As of September 30, 2022 and December 31, 2021, accrued interest receivable from the investments were $0.7 million and $0.1 million, respectively. During the three and nine months ended September 30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September 30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2022 and 2021.
The Company's short-term investments as of September 30, 2022 mature at various dates through June 2023.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories, net Inventories, netInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor.
The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September 30, 2022, we have recorded reserves of finished goods inventories of approximately $2.7 million which were primarily related to process validation batches used for FDA approval.

The components of inventory, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Raw materials$2,217 $2,217 
Work in process20,150 12,566 
Finished goods2,953 4,543 
Total inventories$25,320 $19,326 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses
 9 Months Ended
Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses Prepaid Expenses
Prepaid expenses are as follows:

(in thousands)September 30, 2022December 31, 2021
Prepaid assets$5,725 $5,316 
Prepaid deposits3,582 4,762 
Prepaid insurance2,852 1,632 
Total prepaid expenses$12,159 $11,710 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2022
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,473 $(1,249)$224 
Acquired intellectual property and reacquired rights15,126 (9,580)5,546 
Internal-use software implementation costs2,873 (1,804)1,069 
$19,472 $(12,633)$6,839 
December 31, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,176)$295 
Acquired intellectual property and reacquired rights15,126 (8,804)6,322 
Internal-use software implementation costs2,873 (1,086)1,787 
$19,470 $(11,066)$8,404 
Amortization expense for the three months ended September 30, 2022 and 2021 was $0.5 million for both periods and for the nine months ended September 30, 2022 and 2021 was $1.6 million for both periods.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, net
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Construction in progress$217 $393 
Leasehold improvements2,978 2,978 
Office equipment645 645 
Furniture976 976 
Computer equipment251 262 
5,0675,254
Less accumulated depreciation(1,309)(836)
Property and equipment, net$3,758 $4,418 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Lease Obligations Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.

During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.

On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $0.3 million of CIP cost that was related to the new corporate headquarters.

On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&A.
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.2 million included in the condensed consolidated balance sheets. As of December 31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
As of September 30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&A. The lease is not material to the Company's financial position.
The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for the three and nine months ended September 30, 2022 and September 30, 2021 are $0.2 million and $0.8 million for both periods respectively.
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2022:
As of September 30, 2022
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases8.95.22%
The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2022$263 
20231,061 
20241,085 
20251,110 
20261,135 
Thereafter5,638 
Total future minimum lease payments 10,292 
Less: lease imputed interest(2,104)
Total future minimum lease payments$8,188 
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0 million. The first capital expenditure payment was made in February 2021 of $11.8 million (CHF 10.5 million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $73.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9 million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1 million.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2022December 31, 2021
Employee accruals$16,511 $18,278 
Commercial accruals9,140 5,916 
Accrued R&D projects8,995 6,412 
Other accrued liabilities5,411 3,527 
Income taxes payable66 814 
Total accounts payable and accrued liabilities$40,123 $34,947 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Compensation and Other Non-current Liabilities
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Deferred Compensation and Other Non-current Liabilities Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $15.8 million and $16.0 million as of September 30, 2022 and December 31, 2021, respectively. The balance as of September 30, 2022 and December 31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
License and Collaboration Agreement
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreement License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.

As part of the agreement, the Company received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.

In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.

On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. The approval triggered a $30.0 million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September 30, 2022 and was subsequently received on October 31, 2022.

For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.4 million, respectively, of collaboration service revenue from Otsuka.

Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0 million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Common Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss per Common Share Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2022202120222021
Net loss$(8,989)$(50,255)$(82,134)$(147,644)
Weighted average common shares outstanding141,856 128,443 141,831 128,084 
Net loss per common share (expressed in $ per share)$(0.06)$(0.39)
(0.58)
(1.15)
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Nine months ended
September 30,
(in thousands)20222021
Stock options14,299 12,837 
Unvested performance awards— 857 
Unvested restricted units2,098 201 
Warrants— 1,012 
16,397 14,907 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.
During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month Offering Period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price.

As a result of the modification, $475 thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new 12 month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new 12 month offering period; therefore, the modification also resulted in a “repurchase for no consideration” under ASC 718. The Company recognized an additional $651 thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.
In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.
Stock Options
The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2022 and September 30, 2021:
20222021
Annualized volatility70 %66 %
Risk-free interest rate2.01 %0.38 %
Expected life of options in years5.0 years4.0 years
Estimated forfeiture rate12.1 %8.9 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.60 $6.64 

The following table summarizes the option award activity for the nine months ended September 30, 2022:

September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 202112,074 $12.84 
Granted3,809 11.25 
Exercised(77)6.47 
Forfeited(1,507)14.63 
Outstanding - September 30, 202214,299 $12.26 
Performance Awards and Restricted Stock Units
On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.
On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant.
During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.
The following table summarizes the PA and RSU activity for the nine months ended September 30, 2022:
September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2021347 $13.33 
Granted2,311 11.26 
Vested(305)14.17 
Forfeited(255)12.39 
Outstanding - September 30, 20222,098 $11.04 
Compensation Expense
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2022 and September 30, 2021 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2022202120222021
Research and development$1,489 $1,038 $3,531 $3,201 
Selling, general and administrative6,625 6,000 21,480 19,189 
Capitalized under inventories206 54 387 276 
Share-based compensation expense$8,320 $7,092 $25,398 $22,666 
As of September 30, 2022, there was $33.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective tax rates for the three and nine months ended September 30, 2022 and September 30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $1.0 million for the three and nine months ended September 30, 2022. The Company recognized an income tax expense of approximately $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.

Uncertain Tax Positions

The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September 30, 2022.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $6.0 million upon achievement of specific milestones. The amount payable to ILJIN is nil as of September 30, 2022 and December 31, 2021.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitment and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies
will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and the quarterly report for the quarter ended September 30, 2022.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The Company’s Compensation Committee granted 4 new employees an aggregate of 20,800 inducement stock options and an aggregate of 12,500 inducement RSUs. The options have a per share exercise price of $7.52, the closing price of Aurinia's common stock on September 30, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).
On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D., Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022.

Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Restricted cash Restricted cash: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7 million and $0.3 million as of September 30, 2022 and December 31, 2021, respectively.
Major Customers Major Customers: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September 30, 2022 and 74% for the nine months ended September 30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September 30, 2022 of the Company's total revenues.In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses.
Product Revenues
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.
Milestone Payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be
included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Accounts receivable, net Accounts receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September 30, 2022 and December 31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September 30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September 30, 2022 and as of December 31, 2021
Share-based Compensation Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.
Recently adopted accounting pronouncements
Recently adopted accounting pronouncements
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.
In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:
September 30, 2022
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security— 4,904 — 4,904 
Corporate bond— 98,068 — 98,068 
Commercial paper112,633 — — 112,633 
Treasury bill— 26,704 — 26,704 
Treasury bond— 44,553 — 44,553 
Yankee bond— 3,730 — 3,730 
Total financial assets$198,685 $177,959 $— $376,644 
December 31, 2021
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit— 3,140 — 3,140 
Corporate bond— 21,820 — 21,820 
Commercial paper206,724 — — 206,724 
Treasury bill— 2,494 — 2,494 
Total financial assets$438,624 $27,454 $— $466,078 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments
September 30, 2022
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$86,052 $— $— $86,052 
U.S. agency security4,900 4 — 4,904 
Corporate bond98,448 — (380)98,068 
Commercial paper112,833 — (200)112,633 
Treasury bill26,721 — (17)26,704 
Treasury bond44,670 — (117)44,553 
Yankee bond3,742 — (12)3,730 
Total cash, cash equivalents, restricted cash and short-term investments$377,366 $4 $(726)$376,644 
December 31, 2021
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents and restricted cash$231,900 $— $— $231,900 
Certificates of deposit3,144 — (4)3,140 
Corporate bond2,592 — (1)2,591 
Commercial paper206,764 — (40)206,724 
Treasury bill2,497 — (2)2,495 
Total$446,897 $— $(47)$446,850 
Total held to maturity securities at amortized cost19,228 
Total cash, cash equivalents, restricted cash and short-term investments$466,078 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories, net
The components of inventory, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Raw materials$2,217 $2,217 
Work in process20,150 12,566 
Finished goods2,953 4,543 
Total inventories$25,320 $19,326 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses (Tables)
 9 Months Ended
Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid expenses are as follows:

(in thousands)September 30, 2022December 31, 2021
Prepaid assets$5,725 $5,316 
Prepaid deposits3,582 4,762 
Prepaid insurance2,852 1,632 
Total prepaid expenses$12,159 $11,710 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2022
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,473 $(1,249)$224 
Acquired intellectual property and reacquired rights15,126 (9,580)5,546 
Internal-use software implementation costs2,873 (1,804)1,069 
$19,472 $(12,633)$6,839 
December 31, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,176)$295 
Acquired intellectual property and reacquired rights15,126 (8,804)6,322 
Internal-use software implementation costs2,873 (1,086)1,787 
$19,470 $(11,066)$8,404 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2022December 31, 2021
Construction in progress$217 $393 
Leasehold improvements2,978 2,978 
Office equipment645 645 
Furniture976 976 
Computer equipment251 262 
5,0675,254
Less accumulated depreciation(1,309)(836)
Property and equipment, net$3,758 $4,418 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Lease, Cost
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2022:
As of September 30, 2022
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases8.95.22%
Lessee, Operating Lease, Liability, Maturity
The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2022$263 
20231,061 
20241,085 
20251,110 
20261,135 
Thereafter5,638 
Total future minimum lease payments 10,292 
Less: lease imputed interest(2,104)
Total future minimum lease payments$8,188 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2022December 31, 2021
Employee accruals$16,511 $18,278 
Commercial accruals9,140 5,916 
Accrued R&D projects8,995 6,412 
Other accrued liabilities5,411 3,527 
Income taxes payable66 814 
Total accounts payable and accrued liabilities$40,123 $34,947 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Common Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Loss Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2022202120222021
Net loss$(8,989)$(50,255)$(82,134)$(147,644)
Weighted average common shares outstanding141,856 128,443 141,831 128,084 
Net loss per common share (expressed in $ per share)$(0.06)$(0.39)
(0.58)
(1.15)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share
The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:
Nine months ended
September 30,
(in thousands)20222021
Stock options14,299 12,837 
Unvested performance awards— 857 
Unvested restricted units2,098 201 
Warrants— 1,012 
16,397 14,907 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2022 and September 30, 2021:
20222021
Annualized volatility70 %66 %
Risk-free interest rate2.01 %0.38 %
Expected life of options in years5.0 years4.0 years
Estimated forfeiture rate12.1 %8.9 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.60 $6.64 
Schedule of Option Activity
The following table summarizes the option award activity for the nine months ended September 30, 2022:

September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 202112,074 $12.84 
Granted3,809 11.25 
Exercised(77)6.47 
Forfeited(1,507)14.63 
Outstanding - September 30, 202214,299 $12.26 
Schedule of Performance Shares Activity
The following table summarizes the PA and RSU activity for the nine months ended September 30, 2022:
September 30, 2022
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2021347 $13.33 
Granted2,311 11.26 
Vested(305)14.17 
Forfeited(255)12.39 
Outstanding - September 30, 20222,098 $11.04 
Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2022 and September 30, 2021 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2022202120222021
Research and development$1,489 $1,038 $3,531 $3,201 
Selling, general and administrative6,625 6,000 21,480 19,189 
Capitalized under inventories206 54 387 276 
Share-based compensation expense$8,320 $7,092 $25,398 $22,666 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Property, Plant and Equipment [Line Items]          
Number of operating segments | segment     1    
Cash and cash equivalents and investments $ 376,600,000   $ 376,600,000    
Restricted cash 700,000   700,000   $ 300,000
Revenues 55,779,000 $ 14,667,000 105,595,000 $ 22,201,000  
Accounts receivable, net 41,771,000   41,771,000   15,414,000
Allowance for doubtful accounts 0   0   $ 0
Upfront license and milestone expense     0 10,000,000  
Upfront license payment     0 $ (6,000,000)  
Otuska          
Property, Plant and Equipment [Line Items]          
Accounts receivable, net $ 28,800,000   28,800,000    
Milestone Achievement          
Property, Plant and Equipment [Line Items]          
Revenues     $ 30,000,000    
Minimum          
Property, Plant and Equipment [Line Items]          
Receivable standard credit terms (in days)     30 days    
Maximum          
Property, Plant and Equipment [Line Items]          
Receivable standard credit terms (in days)     45 days    
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One | United States          
Property, Plant and Equipment [Line Items]          
Concentration risk (as percent) 48.00%   74.00%    
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One | Outside United States          
Property, Plant and Equipment [Line Items]          
Concentration risk (as percent) 52.00%   26.00%    
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Financial assets:    
Total financial assets $ 376,644 $ 466,078
Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets 86,052 231,900
U.S. agency security    
Financial assets:    
Total financial assets 4,904  
Certificates of deposit    
Financial assets:    
Total financial assets   3,140
Corporate bond    
Financial assets:    
Total financial assets 98,068 21,820
Commercial paper    
Financial assets:    
Total financial assets 112,633 206,724
Treasury bill    
Financial assets:    
Total financial assets 26,704 2,494
Treasury bond    
Financial assets:    
Total financial assets 44,553  
Yankee bond    
Financial assets:    
Total financial assets 3,730  
Level 1    
Financial assets:    
Total financial assets $ 198,685 $ 438,624
Derivative, average remaining maturity 7 months 8 months
Level 1 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets $ 86,052 $ 231,900
Level 1 | U.S. agency security    
Financial assets:    
Total financial assets 0  
Level 1 | Certificates of deposit    
Financial assets:    
Total financial assets   0
Level 1 | Corporate bond    
Financial assets:    
Total financial assets 0 0
Level 1 | Commercial paper    
Financial assets:    
Total financial assets 112,633 206,724
Level 1 | Treasury bill    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bond    
Financial assets:    
Total financial assets 0  
Level 1 | Yankee bond    
Financial assets:    
Total financial assets 0  
Level 2    
Financial assets:    
Total financial assets $ 177,959 $ 27,454
Derivative, average remaining maturity 7 months 8 months
Level 2 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets $ 0 $ 0
Level 2 | U.S. agency security    
Financial assets:    
Total financial assets 4,904  
Level 2 | Certificates of deposit    
Financial assets:    
Total financial assets   3,140
Level 2 | Corporate bond    
Financial assets:    
Total financial assets 98,068 21,820
Level 2 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 2 | Treasury bill    
Financial assets:    
Total financial assets 26,704 2,494
Level 2 | Treasury bond    
Financial assets:    
Total financial assets 44,553  
Level 2 | Yankee bond    
Financial assets:    
Total financial assets 3,730  
Level 3    
Financial assets:    
Total financial assets 0 0
Level 3 | Cash, cash equivalents and restricted cash    
Financial assets:    
Total financial assets 0 0
Level 3 | U.S. agency security    
Financial assets:    
Total financial assets 0  
Level 3 | Certificates of deposit    
Financial assets:    
Total financial assets   0
Level 3 | Corporate bond    
Financial assets:    
Total financial assets 0 0
Level 3 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bill    
Financial assets:    
Total financial assets 0 $ 0
Level 3 | Treasury bond    
Financial assets:    
Total financial assets 0  
Level 3 | Yankee bond    
Financial assets:    
Total financial assets $ 0  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]      
Total cash, cash equivalents, restricted cash and short-term investments $ 376,600 $ 376,600 $ 466,078
Available-for-sale debt securities 376,600 376,600 446,900
Total held to maturity securities at amortized cost     19,228
Interest receivable 700 700 $ 100
Unrealized gains on available-for-sale securities $ 300 $ (700)  
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Marketable Securities [Line Items]    
Amortized Cost $ 377,366 $ 446,897
Unrealized Gains 4 0
Unrealized Losses (726) (47)
Estimated Fair Value 376,644 446,850
Total held to maturity securities at amortized cost   19,228
Total cash, cash equivalents, restricted cash and short-term investments 376,600 466,078
Cash, cash equivalents and restricted cash    
Marketable Securities [Line Items]    
Amortized Cost 86,052 231,900
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 86,052 231,900
Certificates of deposit    
Marketable Securities [Line Items]    
Amortized Cost 4,900 3,144
Unrealized Gains 4 0
Unrealized Losses 0 (4)
Estimated Fair Value 4,904 3,140
Corporate bond    
Marketable Securities [Line Items]    
Amortized Cost 98,448 2,592
Unrealized Gains 0 0
Unrealized Losses (380) (1)
Estimated Fair Value 98,068 2,591
Commercial paper    
Marketable Securities [Line Items]    
Amortized Cost 112,833 206,764
Unrealized Gains 0 0
Unrealized Losses (200) (40)
Estimated Fair Value 112,633 206,724
Treasury bill    
Marketable Securities [Line Items]    
Amortized Cost 26,721 2,497
Unrealized Gains 0 0
Unrealized Losses (17) (2)
Estimated Fair Value 26,704 $ 2,495
Treasury bond    
Marketable Securities [Line Items]    
Amortized Cost 44,670  
Unrealized Gains 0  
Unrealized Losses (117)  
Estimated Fair Value 44,553  
Yankee bond    
Marketable Securities [Line Items]    
Amortized Cost 3,742  
Unrealized Gains 0  
Unrealized Losses (12)  
Estimated Fair Value $ 3,730  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Finished goods inventories $ 2,700  
Raw materials 2,217 $ 2,217
Work in process 20,150 12,566
Finished goods 2,953 4,543
Total inventories $ 25,320 $ 19,326
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Prepaid Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 5,725 $ 5,316
Prepaid deposits 3,582 4,762
Prepaid insurance 2,852 1,632
Prepaid expenses $ 12,159 $ 11,710
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 19,472 $ 19,470
Accumulated Amortization (12,633) (11,066)
Net Carrying Amount 6,839 8,404
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1,473 1,471
Accumulated Amortization (1,249) (1,176)
Net Carrying Amount 224 295
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 15,126 15,126
Accumulated Amortization (9,580) (8,804)
Net Carrying Amount 5,546 6,322
Internal-use software implementation costs    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,873 2,873
Accumulated Amortization (1,804) (1,086)
Net Carrying Amount $ 1,069 $ 1,787
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 0.5 $ 0.5 $ 1.6 $ 1.6
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 5,067 $ 5,254
Less accumulated depreciation (1,309) (836)
Property and equipment, net 3,758 4,418
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 217 393
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 2,978 2,978
Office equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 645 645
Furniture    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 976 976
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 251 $ 262
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations - Narrative (Details)
$ in Thousands, SFr in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 03, 2022
USD ($)
Dec. 31, 2021
USD ($)
Feb. 28, 2021
USD ($)
Feb. 28, 2021
CHF (SFr)
Jan. 31, 2021
CHF (SFr)
Mar. 31, 2020
ft²
extension_option
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
Mar. 12, 2020
Lessee, Lease, Description [Line Items]                        
Capital expenditure payments     $ 11,800 SFr 10.5                
Right-of-use assets, net   $ 5,383         $ 4,945   $ 4,945      
Total lease liabilities             $ 8,188   $ 8,188      
Incremental borrowing rate             5.22%   5.22%      
Operating lease costs             $ 200 $ 200 $ 800 $ 800    
Payments for capital improvements | SFr         SFr 21.0              
Minimum finance lease liability payments due             73,000   73,000      
Expected payments prior to commencement of lease             900   900      
Future value of minimum lease payments of leases not yet commenced             100   100      
Victoria, British Columbia                        
Lessee, Lease, Description [Line Items]                        
Lease term                     18 months  
Capital expenditure payments $ 300                      
Rockville, Maryland                        
Lessee, Lease, Description [Line Items]                        
Lease term           11 years            
Area of property (in sqft) | ft²           30,531            
Remaining lease term           9 years            
Number of extension options | extension_option           2            
Lease extension term           5 years            
Lease termination option term           7 years            
Right-of-use assets, net   5,200         4,900   4,900      
Total lease liabilities   8,600         $ 8,200   $ 8,200      
Proceeds from tenant improvements   $ 2,300                    
Incremental borrowing rate                       5.20%
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)
Sep. 30, 2022
Leases [Abstract]  
Weighted average remaining lease term - operating leases (in years) 8 years 10 months 24 days
Weighted average discount rate - operating leases 5.22%
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Leases [Abstract]  
Remainder of 2022 $ 263
2023 1,061
2024 1,085
2025 1,110
2026 1,135
Thereafter 5,638
Total future minimum lease payments 10,292
Less: lease imputed interest (2,104)
Total future minimum lease payments $ 8,188
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Employee accruals $ 16,511 $ 18,278
Commercial accruals 9,140 5,916
Accrued R&D projects 8,995 6,412
Other accrued liabilities 5,411 3,527
Income taxes payable 66 814
Accounts payable and accrued liabilities $ 40,123 $ 34,947
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Other non-current liabilities $ 15,833 $ 15,950
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 15, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     $ 55,779   $ 14,667 $ 105,595 $ 22,201  
Research and development     10,973   20,066 35,118 39,990  
Product Sales                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     25,502   $ 14,638 75,142 $ 22,113  
License Agreement Terms | Otuska                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront payments received   $ 50,000            
Potential regulatory milestone revenue   $ 50,000            
Triggered milestone, payments               $ 30,000
License Agreement Terms | Otuska | Service Revenue                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     $ 200     $ 400    
License Agreement Terms | Otuska | Minimum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   10.00%            
License Agreement Terms | Otuska | Maximum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   20.00%            
License Agreement Terms | Riptide Bioscience, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront license fee $ 6,000              
Research and development       $ 4,000        
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]        
Net loss $ (8,989) $ (50,255) $ (82,134) $ (147,644)
Weighted-average common shares outstanding used in computation of basic loss per share (in shares) 141,856 128,443 141,831 128,084
Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) 141,856 128,443 141,831 128,084
Basic loss per share ($ per share) $ (0.06) $ (0.39) $ (0.58) $ (1.15)
Diluted loss per share ($ per share) $ (0.06) $ (0.39) $ (0.58) $ (1.15)
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 16,397,000 14,907,000
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 14,299,000 12,837,000
Unvested performance awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 857,000
Unvested restricted units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 2,098,000 201,000
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 1,012,000
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-based Compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 06, 2021
$ / shares
shares
Mar. 18, 2021
$ / shares
Oct. 23, 2020
shares
Jun. 30, 2021
shares
Sep. 30, 2022
USD ($)
Jun. 30, 2022
purchase_period
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
purchase_period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share-based compensation expense | $         $ 8,320   $ 7,092 $ 25,398 $ 22,666  
Unrecognized share-based compensation expense | $         $ 33,600     $ 33,600    
Unrecognized share-based compensation expense weighted average recognition period               1 year 4 months 24 days    
Employee Stock                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of shares authorized       2,500,000            
Number of purchase periods | purchase_period           2       4
Purchase period           12 months       24 months
Offering period           12 months   12 months    
Share-based compensation expense | $               $ 475    
Unamortized expense | $               $ 651    
Unvested performance awards | Officer                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares)     439,000              
Granted, weighted average exercise price (in usd per share) | $ / shares   $ 13.56                
Performance Share sand Restricted Stock Units (RSUs) | Officer                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares) 619,000             2,311,000    
Granted, weighted average exercise price (in usd per share) | $ / shares $ 14.42             $ 11.26    
Performance shares vested (in shares)               305,000    
Shares forfeited/canceled (in shares)               255,000    
Unvested restricted units                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Award vesting period               1 year    
Amended and Restated Equity Incentive Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of additional shares authorized       23,800,000            
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]    
Annualized volatility(as percent) 70.00% 66.00%
Risk-free interest rate (as percent) 2.01% 0.38%
Expected life of options in years 5 years 4 years
Estimated forfeiture rate (as percent) 12.10% 8.90%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 6.60 $ 6.64
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Stock Option Activity (Details) - $ / shares
shares in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Number of shares (in thousands)    
Beginning balance (in shares) 12,074  
Granted (in shares) 3,809  
Exercised (in shares) (77)  
Forfeited (in shares) (1,507)  
Ending balance (in shares) 14,299  
Weighted average exercise price $    
Beginning balance (in usd per share) $ 12.26 $ 12.84
Granted (in usd per share) 11.25  
Exercised (in usd per share) 6.47  
Forfeited (in usd per share) 14.63  
Ending balance (in usd per share) $ 12.26  
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Performance Share sand Restricted Stock Units (RSUs) - Officer - $ / shares
shares in Thousands
 9 Months Ended
Aug. 06, 2021
Sep. 30, 2022
Number of shares (in thousands)    
Outstanding - Beginning of Period (in shares)   347
Granted (in shares) 619 2,311
Performance shares vested (in shares)   (305)
Performance shares forfeited (in shares)   (255)
Outstanding - End of Period (in shares)   2,098
Weighted average exercise price $    
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)   $ 13.33
Performance shares awards, weighted average grant date fair value (in usd per share) $ 14.42 11.26
Performance shares vested, Weighted average grant date fair value (in usd per share)   14.17
Performance share forfeited, Weighted average exercise price (in usd per share)   12.39
Outstanding, Weighted average exercise price - End of Period (in usd per share)   $ 11.04
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 8,320 $ 7,092 $ 25,398 $ 22,666
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 1,489 1,038 3,531 3,201
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 6,625 6,000 21,480 19,189
Capitalized under inventories        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 206 $ 54 $ 387 $ 276
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ 954 $ 8 $ 973 $ 34
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions (Details) - ILJIN - USD ($)
 12 Months Ended
Dec. 31, 2021
Sep. 30, 2022
Other Current Liabilities    
Related Party Transaction [Line Items]    
Due to related parties $ 0 $ 0
Milestone Payment | Affiliated Shareholder    
Related Party Transaction [Line Items]    
Payments to related party $ 6,000,000  
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details)
 9 Months Ended
Sep. 30, 2022
employee
$ / shares
shares
Sep. 30, 2022
$ / shares
shares
Subsequent Event [Line Items]    
Granted (in shares)   3,809,000
Granted (in usd per share) | $ / shares   $ 11.25
New Employees    
Subsequent Event [Line Items]    
Number of new employees | employee 4  
New Employees | Inducement Stock Option    
Subsequent Event [Line Items]    
Granted (in shares) 20,800  
Granted (in usd per share) | $ / shares $ 7.52  
New Employees | Restricted Stock Units (RSUs)    
Subsequent Event [Line Items]    
Granted (in shares) 12,500  
XML 77 auph-20220930_htm.xml IDEA: XBRL DOCUMENT 0001600620 2022-01-01 2022-09-30 0001600620 2022-11-02 0001600620 2022-09-30 0001600620 2021-12-31 0001600620 us-gaap:ProductMember 2022-07-01 2022-09-30 0001600620 us-gaap:ProductMember 2021-07-01 2021-09-30 0001600620 us-gaap:ProductMember 2022-01-01 2022-09-30 0001600620 us-gaap:ProductMember 2021-01-01 2021-09-30 0001600620 us-gaap:LicenseMember 2022-07-01 2022-09-30 0001600620 us-gaap:LicenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:LicenseMember 2022-01-01 2022-09-30 0001600620 us-gaap:LicenseMember 2021-01-01 2021-09-30 0001600620 2022-07-01 2022-09-30 0001600620 2021-07-01 2021-09-30 0001600620 2021-01-01 2021-09-30 0001600620 us-gaap:CommonStockMember 2022-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001600620 us-gaap:RetainedEarningsMember 2022-06-30 0001600620 2022-06-30 0001600620 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001600620 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001600620 us-gaap:CommonStockMember 2022-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001600620 us-gaap:RetainedEarningsMember 2022-09-30 0001600620 us-gaap:CommonStockMember 2021-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001600620 us-gaap:RetainedEarningsMember 2021-06-30 0001600620 2021-06-30 0001600620 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001600620 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001600620 us-gaap:CommonStockMember 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001600620 us-gaap:RetainedEarningsMember 2021-09-30 0001600620 2021-09-30 0001600620 us-gaap:CommonStockMember 2021-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001600620 us-gaap:RetainedEarningsMember 2021-12-31 0001600620 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001600620 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001600620 us-gaap:CommonStockMember 2020-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001600620 us-gaap:RetainedEarningsMember 2020-12-31 0001600620 2020-12-31 0001600620 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001600620 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001600620 auph:SpecialtyPharmacyOneMember country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001600620 auph:SpecialtyPharmacyOneMember country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001600620 auph:SpecialtyPharmacyOneMember auph:OutsideUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001600620 auph:SpecialtyPharmacyOneMember auph:OutsideUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001600620 auph:MilestoneAchievementMember 2022-01-01 2022-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember 2022-09-30 0001600620 srt:MinimumMember 2022-01-01 2022-09-30 0001600620 srt:MaximumMember 2022-01-01 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2022-09-30 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:USAgencySecurityMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member auph:USAgencySecurityMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member auph:USAgencySecurityMember 2022-09-30 0001600620 auph:USAgencySecurityMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2022-09-30 0001600620 us-gaap:CorporateBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-09-30 0001600620 us-gaap:CommercialPaperMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2022-09-30 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBondSecuritiesMember 2022-09-30 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:YankeeBondMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member auph:YankeeBondMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member auph:YankeeBondMember 2022-09-30 0001600620 auph:YankeeBondMember 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001600620 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001600620 us-gaap:FairValueInputsLevel1Member auph:CashCashEquivalentsAndRestrictedCashMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member auph:CashCashEquivalentsAndRestrictedCashMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member auph:CashCashEquivalentsAndRestrictedCashMember 2021-12-31 0001600620 auph:CashCashEquivalentsAndRestrictedCashMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2021-12-31 0001600620 us-gaap:CertificatesOfDepositMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2021-12-31 0001600620 us-gaap:CommercialPaperMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001600620 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2022-01-01 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-09-30 0001600620 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2021-01-01 2021-12-31 0001600620 us-gaap:CertificatesOfDepositMember 2022-09-30 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2022-09-30 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2021-12-31 0001600620 us-gaap:PatentsMember 2022-09-30 0001600620 us-gaap:IntellectualPropertyMember 2022-09-30 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-09-30 0001600620 us-gaap:PatentsMember 2021-12-31 0001600620 us-gaap:IntellectualPropertyMember 2021-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-12-31 0001600620 us-gaap:ConstructionInProgressMember 2022-09-30 0001600620 us-gaap:ConstructionInProgressMember 2021-12-31 0001600620 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001600620 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001600620 us-gaap:OfficeEquipmentMember 2022-09-30 0001600620 us-gaap:OfficeEquipmentMember 2021-12-31 0001600620 us-gaap:FurnitureAndFixturesMember 2022-09-30 0001600620 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001600620 us-gaap:ComputerEquipmentMember 2022-09-30 0001600620 us-gaap:ComputerEquipmentMember 2021-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2020-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2022-08-03 2022-08-03 0001600620 auph:RockvilleMarylandMember 2020-03-31 0001600620 auph:RockvilleMarylandMember 2020-03-01 2020-03-31 0001600620 auph:RockvilleMarylandMember 2022-09-30 0001600620 auph:RockvilleMarylandMember 2021-12-31 0001600620 auph:RockvilleMarylandMember 2021-12-31 2021-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-12 0001600620 2021-01-01 2021-01-31 0001600620 2021-02-01 2021-02-28 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2022-09-15 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2022-07-01 2022-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:ServiceMember us-gaap:LicenseAgreementTermsMember 2022-01-01 2022-09-30 0001600620 auph:RiptideBioscienceIncMember us-gaap:LicenseAgreementTermsMember 2021-08-17 2021-08-17 0001600620 auph:RiptideBioscienceIncMember us-gaap:LicenseAgreementTermsMember 2022-01-01 2022-03-31 0001600620 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001600620 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001600620 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001600620 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001600620 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001600620 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001600620 auph:AmendedAndRestatedEquityIncentivePlanMember 2021-06-01 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001600620 us-gaap:EmployeeStockMember 2022-04-01 2022-06-30 0001600620 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-10-23 2020-10-23 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-03-18 2021-03-18 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2021-08-06 2021-08-06 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2021-12-31 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2022-01-01 2022-09-30 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2022-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001600620 us-gaap:InventoriesMember 2022-07-01 2022-09-30 0001600620 us-gaap:InventoriesMember 2021-07-01 2021-09-30 0001600620 us-gaap:InventoriesMember 2022-01-01 2022-09-30 0001600620 us-gaap:InventoriesMember 2021-01-01 2021-09-30 0001600620 auph:ILJINMember auph:MilestonePaymentMember srt:AffiliatedEntityMember 2021-01-01 2021-12-31 0001600620 auph:ILJINMember us-gaap:OtherCurrentLiabilitiesMember 2021-12-31 0001600620 auph:ILJINMember us-gaap:OtherCurrentLiabilitiesMember 2022-09-30 0001600620 auph:NewEmployeesMember 2022-09-30 2022-09-30 0001600620 auph:NewEmployeesMember auph:ShareBasedPaymentArrangementInducementOptionMember 2022-09-30 2022-09-30 0001600620 auph:NewEmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 2022-09-30 shares iso4217:USD iso4217:USD shares auph:segment pure utr:sqft auph:extension_option iso4217:CHF auph:purchase_period auph:employee false 2022 Q3 0001600620 --12-31 10-Q true 2022-09-30 false 001-36421 Aurinia Pharmaceuticals Inc. Z4 #1203-4464 Markham Street Victoria BC V8Z 7X8 98-1231763 (250) 744-2487 Yes Yes Large Accelerated Filer false false false 142109703 Common shares, no par value AUPH NASDAQ 86052000 231900000 290592000 234178000 41771000 15414000 25320000 19326000 12159000 11710000 3808000 796000 459702000 513324000 13049000 11838000 3758000 4418000 6839000 8404000 4945000 5383000 488293000 543367000 40123000 34947000 724000 4640000 918000 1059000 41765000 40646000 15833000 15950000 7270000 7680000 64868000 64276000 0 0 142110000 142110000 141600000 141600000 1184020000 1177051000 79188000 59014000 -1527000 -852000 -838256000 -756122000 423425000 479091000 488293000 543367000 25502000 14638000 75142000 22113000 30277000 29000 30453000 88000 55779000 14667000 105595000 22201000 2447000 254000 4302000 610000 52169000 44645000 148898000 128772000 10973000 20066000 35118000 39990000 311000 -55000 -647000 -859000 65278000 65020000 188965000 170231000 -9499000 -50353000 -83370000 -148030000 1464000 106000 2209000 420000 -8035000 -50247000 -81161000 -147610000 954000 8000 973000 34000 -8989000 -50255000 -82134000 -147644000 0 0 0 0 326000 -2000 -675000 11000 -8663000 -50257000 -82809000 -147633000 -0.06 -0.06 -0.39 -0.39 -0.58 -0.58 -1.15 -1.15 141856000 141856000 128443000 128443000 141831000 141831000 128084000 128084000 141892000 1180884000 74004000 -1853000 -829267000 423768000 218000 3136000 -3136000 0 8320000 8320000 326000 326000 -8989000 -8989000 142110000 1184020000 79188000 -1527000 -838256000 423425000 128396000 954572000 51022000 -792000 -672545000 332257000 1172000 12579000 -3505000 9074000 2000 8000 -2000 6000 7092000 7092000 -2000 -2000 -50255000 -50255000 129570000 967159000 54607000 -794000 -722800000 298172000 141600000 1177051000 59014000 -852000 -756122000 479091000 383000 5064000 -4542000 522000 127000 1905000 -682000 1223000 25398000 25398000 -675000 -675000 -82134000 -82134000 142110000 1184020000 79188000 -1527000 -838256000 423425000 126725000 944328000 39383000 -805000 -575156000 407750000 2324000 22097000 -6745000 15352000 521000 734000 -697000 37000 22666000 22666000 11000 11000 -147644000 -147644000 129570000 967159000 54607000 -794000 -722800000 298172000 -82134000 -147644000 2487000 2030000 0 10000000 25398000 22666000 2464000 0 -587000 -1005000 26356000 9815000 8458000 5366000 3461000 6541000 830000 -247000 875000 1149000 -551000 499000 -89979000 -131770000 403184000 342831000 346109000 263752000 381000 11838000 0 6000000 158000 268000 0 1198000 -57614000 -98383000 1745000 15353000 0 37000 1745000 15390000 -145848000 -214763000 231900000 272350000 86052000 57587000 1705000 671000 779000 236000 897000 195000 0 419000 85341000 57587000 711000 0 86052000 57587000 Organization and Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as our other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka Pharmaceutical Co., Ltd. (Otsuka). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all European (EU) member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.</span></div> Summary of Significant Accounting Policies <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency, therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $376.6 million as of September 30, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7 million and $0.3 million as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September 30, 2022 and 74% for the nine months ended September 30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September 30, 2022 of the Company's total revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. As of September 30, 2022, we recognized $30.0 million for the regulatory milestone related to the EC marketing authorization of LUPKYNIS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September 30, 2022 and December 31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September 30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September 30, 2022 and as of December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div> 1 376600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.7 million and $0.3 million as of September 30, 2022 and December 31, 2021, respectively.</span> 700000 300000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories"). Revenues from the two main customers in the U.S. accounted in total of approximately 48% for the three months ended September 30, 2022 and 74% for the nine months ended September 30, 2022 of the Company's total revenues. Our collaboration partner for sales outside the U.S. accounted for approximately 52% and 26% for the three and nine months ended September 30, 2022 of the Company's total revenues.</span>In late March 2022, we provided a nominal additional discount to both of our two main U.S. customers, applicable for the remainder of the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. 0.48 0.74 0.52 0.26 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which typically occurs upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2022, we did not have any material adjustments to estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be </span></div>included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur. 30000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). Milestone payments that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of September 30, 2022 and December 31, 2021, accounts receivable, net are $41.8 million and $15.4 million. The accounts receivable, net as of September 30, 2022 includes $28.8 million due from Otsuka related to the achievement of a regulatory milestone in September 2022, for which payment was received on October 31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. </span>We estimate the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was $nil as of September 30, 2022 and as of December 31, 2021 41800000 15400000 28800000 P30D P45D 0 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes such as eliminating the exception to the general intraperiod tax allocation principle. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div> Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include cash, cash equivalents, restricted cash and commercial paper that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2022, and December 31, 2021, the weighted average remaining contractual maturities of our Level 1 and 2 investments were approximately for 7 months and 8 months, respectively. These investments have an overall rating of A-1, or higher, by Moody’s, Standard &amp; Poor’s and Fitch.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit loss allowance was recorded as of September 30, 2022, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, “Cash, Cash Equivalents, Restricted Cash and Short-Term Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 86052000 0 0 86052000 0 4904000 0 4904000 0 98068000 0 98068000 112633000 0 0 112633000 0 26704000 0 26704000 0 44553000 0 44553000 0 3730000 0 3730000 198685000 177959000 0 376644000 231900000 0 0 231900000 0 3140000 0 3140000 0 21820000 0 21820000 206724000 0 0 206724000 0 2494000 0 2494000 438624000 27454000 0 466078000 P7M P7M P8M P8M Cash, Cash Equivalents, Restricted Cash and Short-Term Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company had $376.6 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments summarized below. As of September 30, 2022, $376.6 million were available-for-sale debt securities which are carried at fair market value. As of December 31, 2021, $446.9 million were classified as available-for-sale and $19.2 million were held-to-maturity. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(726)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total held to maturity securities at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, accrued interest receivable from the investments were $0.7 million and $0.1 million, respectively. During the three and nine months ended September 30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely we will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. We have determined that the gross unrealized losses on our investments at September 30, 2022, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2022 and 2021.</span></div>The Company's short-term investments as of September 30, 2022 mature at various dates through June 2023. 376600000 466100000 376600000 446900000 19200000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,052</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency security</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,553</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">377,366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(726)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">376,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury bill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,897 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total held to maturity securities at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 86052000 0 0 86052000 4900000 4000 0 4904000 98448000 0 380000 98068000 112833000 0 200000 112633000 26721000 0 17000 26704000 44670000 0 117000 44553000 3742000 0 12000 3730000 377366000 4000 726000 376644000 231900000 0 0 231900000 3144000 0 4000 3140000 2592000 0 1000 2591000 206764000 0 40000 206724000 2497000 0 2000 2495000 446897000 0 47000 446850000 19228000 466078000 700000 100000 300000 -700000 Inventories, netInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September 30, 2022, we have recorded reserves of finished goods inventories of approximately $2.7 million which were primarily related to process validation batches used for FDA approval.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory, net are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,150</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2217000 2217000 20150000 12566000 2953000 4543000 25320000 19326000 Prepaid Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,710 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,710 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5725000 5316000 3582000 4762000 2852000 1632000 12159000 11710000 Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September 30, 2022 and 2021 was $0.5 million for both periods and for the nine months ended September 30, 2022 and 2021 was $1.6 million for both periods.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1473000 1249000 224000 15126000 9580000 5546000 2873000 1804000 1069000 19472000 12633000 6839000 1471000 1176000 295000 15126000 8804000 6322000 2873000 1086000 1787000 19470000 11066000 8404000 500000 500000 1600000 1600000 Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,067</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,067</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 217000 393000 2978000 2978000 645000 645000 976000 976000 251000 262000 5067000 5254000 1309000 836000 3758000 4418000 Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the company expensed $0.3 million of CIP cost that was related to the new corporate headquarters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&amp;A.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.2 million included in the condensed consolidated balance sheets. As of December 31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has a short term lease in Edmonton, Alberta in which expenses are recognized in SG&amp;A. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the three and nine months ended September 30, 2022 and September 30, 2021 are $0.2 million and $0.8 million for both periods respectively.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0 million. The first capital expenditure payment was made in February 2021 of $11.8 million (CHF 10.5 million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $73.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div>The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9 million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1 million. P18M 300000 30531 P9Y 2 P5Y P11Y P7Y 4900000 8200000 5200000 8600000 -2300000 0.052 200000 200000 800000 800000 <div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22%</span></td></tr></table></div> P8Y10M24D 0.0522 <div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 263000 1061000 1085000 1110000 1135000 5638000 10292000 2104000 8188000 21000000 11800000 10500000 73000000 900000 100000 Accounts Payable and Accrued Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,511</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,140</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16511000 18278000 9140000 5916000 8995000 6412000 5411000 3527000 66000 814000 40123000 34947000 Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $15.8 million and $16.0 million as of September 30, 2022 and December 31, 2021, respectively. The balance as of September 30, 2022 and December 31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future. 15800000 16000000 License and Collaboration Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, the Company received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval triggered a $30.0 million milestone to the Company, which was recognized as collaboration revenue in the three and nine months period ended September 30, 2022 and was subsequently received on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, the Company recognized $0.2 million and $0.4 million, respectively, of collaboration service revenue from Otsuka. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0 million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.</span></div> 50000000 50000000 0.10 0.20 30000000 200000 400000 6000000 4000000 Net Loss per Common Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.58)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.58)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></div></td></tr></table> -8989000 -50255000 -82134000 -147644000 141856000 141856000 128443000 128443000 141831000 141831000 128084000 128084000 -0.06 -0.06 -0.39 -0.39 -0.58 -0.58 -1.15 -1.15 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14299000 12837000 0 857000 2098000 201000 0 1012000 16397000 14907000 Share-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards, and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month Offering Period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the modification, $475 thousand of incremental expense was added to the estimated expense for the November 2022 and May 2023 purchase dates (to be amortized over the new 12 month offering period). Additionally, the originally scheduled purchase date in November 2023 is no longer planned given the new 12 month offering period; therefore, the modification also resulted in a “repurchase for no consideration” under ASC 718. The Company recognized an additional $651 thousand of unamortized expense for the cancelled November 2023 purchase, which was recorded during the second quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to stock options, performance awards and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2022 and September 30, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2022, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PA and RSU activity for the nine months ended September 30, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2022 and September 30, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, there was $33.6 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.</span></div> 23800000 2500000 4 P24M 2 P12M P12M 475000 P12M P12M 651000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2022 and September 30, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.70 0.66 0.0201 0.0038 P5Y P4Y 0.121 0.089 0.000 0.000 6.60 6.64 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity for the nine months ended September 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 12074000 12.84 3809000 11.25 77000 6.47 1507000 14.63 14299000 12.26 439000 13.56 619000 14.42 P1Y <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PA and RSU activity for the nine months ended September 30, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,098</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 347000 13.33 2311000 11.26 305000 14.17 255000 12.39 2098000 11.04 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2022 and September 30, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,480</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,320</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1489000 1038000 3531000 3201000 6625000 6000000 21480000 19189000 206000 54000 387000 276000 8320000 7092000 25398000 22666000 33600000 P1Y4M24D Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September 30, 2022 and September 30, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $1.0 million for the three and nine months ended September 30, 2022. The Company recognized an income tax expense of approximately $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions and withholding taxes on foreign income. The Company currently has tax expense in certain jurisdictions that are not offset by tax benefits. The increase from prior periods was due to withholding taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency that the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at September 30, 2022.</span></div> 1000000 1000000 8000 34000 Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During 2021, Aurinia paid ILJIN $6.0 million upon achievement of specific milestones. The amount payable to ILJIN is nil as of September 30, 2022 and December 31, 2021. 6000000 0 0 Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and the quarterly report for the quarter ended September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div> Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Compensation Committee granted 4 new employees an aggregate of 20,800 inducement stock options and an aggregate of 12,500 inducement RSUs. The options have a per share exercise price of $7.52,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the closing price of Aurinia's common stock on September 30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022. The stock options and RSUs have a grant date of October 3, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2022, Aurinia mutually agreed with Robert Huizinga, PhD RN, CNeph(C), Executive Vice President, Research and Neil Solomons, M.D., Chief Medical Officer, to cease their employment with Aurinia, each effective October 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurnia has entered into separation agreements with Dr. Huizinga and Dr. Solomons which will supersede and replace all the severance arrangements between Aurinia and Dr. Huizinga and Dr. Solomons, set forth in their respective employment agreements with Aurinia, dated October 1, 2018 and September 12, 2012, respectively (together, as amended, the Employment Agreements). The terms of the separation agreements are expected to be consistent with the terms of the Employment Agreements, respectively.</span></div> 4 20800 12500 7.52 30000000 EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 201 251 1 false 59 0 false 10 false false R1.htm 0000001 - Document - COVER Sheet http://www.auriniapharma.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Organization and Description of Business Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value Measurements Sheet http://www.auriniapharma.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments Cash, Cash Equivalents, Restricted Cash and Short-Term Investments Notes 11 false false R12.htm 0000012 - Disclosure - Inventories, net Sheet http://www.auriniapharma.com/role/Inventoriesnet Inventories, net Notes 12 false false R13.htm 0000013 - Disclosure - Prepaid Expenses Sheet http://www.auriniapharma.com/role/PrepaidExpenses Prepaid Expenses Notes 13 false false R14.htm 0000014 - Disclosure - Intangible Assets Sheet http://www.auriniapharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Property and Equipment, net Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 15 false false R16.htm 0000016 - Disclosure - Lease Obligations Sheet http://www.auriniapharma.com/role/LeaseObligations Lease Obligations Notes 16 false false R17.htm 0000017 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 17 false false R18.htm 0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities Deferred Compensation and Other Non-current Liabilities Notes 18 false false R19.htm 0000019 - Disclosure - License and Collaboration Agreement Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreement License and Collaboration Agreement Notes 19 false false R20.htm 0000020 - Disclosure - Net Loss per Common Share Sheet http://www.auriniapharma.com/role/NetLossperCommonShare Net Loss per Common Share Notes 20 false false R21.htm 0000021 - Disclosure - Share-based Compensation Sheet http://www.auriniapharma.com/role/SharebasedCompensation Share-based Compensation Notes 21 false false R22.htm 0000022 - Disclosure - Income Taxes Sheet http://www.auriniapharma.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 0000023 - Disclosure - Related-Party Transactions Sheet http://www.auriniapharma.com/role/RelatedPartyTransactions Related-Party Transactions Notes 23 false false R24.htm 0000024 - Disclosure - Commitment and Contingencies Sheet http://www.auriniapharma.com/role/CommitmentandContingencies Commitment and Contingencies Notes 24 false false R25.htm 0000025 - Disclosure - Subsequent Events Sheet http://www.auriniapharma.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 0000027 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.auriniapharma.com/role/FairValueMeasurements 27 false false R28.htm 0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables) Tables http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments 28 false false R29.htm 0000029 - Disclosure - Inventories, net (Tables) Sheet http://www.auriniapharma.com/role/InventoriesnetTables Inventories, net (Tables) Tables http://www.auriniapharma.com/role/Inventoriesnet 29 false false R30.htm 0000030 - Disclosure - Prepaid Expenses (Tables) Sheet http://www.auriniapharma.com/role/PrepaidExpensesTables Prepaid Expenses (Tables) Tables http://www.auriniapharma.com/role/PrepaidExpenses 30 false false R31.htm 0000031 - Disclosure - Intangible Assets (Tables) Sheet http://www.auriniapharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.auriniapharma.com/role/IntangibleAssets 31 false false R32.htm 0000032 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.auriniapharma.com/role/PropertyandEquipmentnet 32 false false R33.htm 0000033 - Disclosure - Lease Obligations (Tables) Sheet http://www.auriniapharma.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.auriniapharma.com/role/LeaseObligations 33 false false R34.htm 0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities 34 false false R35.htm 0000035 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.auriniapharma.com/role/NetLossperCommonShare 35 false false R36.htm 0000036 - Disclosure - Share-based Compensation (Tables) Sheet http://www.auriniapharma.com/role/SharebasedCompensationTables Share-based Compensation (Tables) Tables http://www.auriniapharma.com/role/SharebasedCompensation 36 false false R37.htm 0000037 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies 37 false false R38.htm 0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 38 false false R39.htm 0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details) Details http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables 39 false false R40.htm 0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details) Sheet http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details) Details http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables 40 false false R41.htm 0000041 - Disclosure - Inventories, net (Details) Sheet http://www.auriniapharma.com/role/InventoriesnetDetails Inventories, net (Details) Details http://www.auriniapharma.com/role/InventoriesnetTables 41 false false R42.htm 0000042 - Disclosure - Prepaid Expenses (Details) Sheet http://www.auriniapharma.com/role/PrepaidExpensesDetails Prepaid Expenses (Details) Details http://www.auriniapharma.com/role/PrepaidExpensesTables 42 false false R43.htm 0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 43 false false R44.htm 0000044 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 44 false false R45.htm 0000045 - Disclosure - Property and Equipment, net (Details) Sheet http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails Property and Equipment, net (Details) Details http://www.auriniapharma.com/role/PropertyandEquipmentnetTables 45 false false R46.htm 0000046 - Disclosure - Lease Obligations - Narrative (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails Lease Obligations - Narrative (Details) Details 46 false false R47.htm 0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Details 47 false false R48.htm 0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Details 48 false false R49.htm 0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables 49 false false R50.htm 0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details) Sheet http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails Deferred Compensation and Other Non-current Liabilities (Details) Details http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities 50 false false R51.htm 0000051 - Disclosure - License and Collaboration Agreement (Details) Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails License and Collaboration Agreement (Details) Details http://www.auriniapharma.com/role/LicenseandCollaborationAgreement 51 false false R52.htm 0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 52 false false R53.htm 0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails Net Loss per Common Share - Anti-Dilutive Securities (Details) Details 53 false false R54.htm 0000054 - Disclosure - Share-based Compensation - Narrative (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails Share-based Compensation - Narrative (Details) Details 54 false false R55.htm 0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted Average Assumptions (Details) Details 55 false false R56.htm 0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails Share-Based Compensation - Stock Option Activity (Details) Details 56 false false R57.htm 0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) Details 57 false false R58.htm 0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Details 58 false false R59.htm 0000059 - Disclosure - Income Taxes (Details) Sheet http://www.auriniapharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.auriniapharma.com/role/IncomeTaxes 59 false false R60.htm 0000060 - Disclosure - Related-Party Transactions (Details) Sheet http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.auriniapharma.com/role/RelatedPartyTransactions 60 false false R61.htm 0000061 - Disclosure - Subsequent Events (Details) Sheet http://www.auriniapharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.auriniapharma.com/role/SubsequentEvents 61 false false All Reports Book All Reports auph-20220930.htm auph-20220930.xsd auph-20220930_cal.xml auph-20220930_def.xml auph-20220930_lab.xml auph-20220930_pre.xml auph-2022q3exx311.htm auph-2022q3exx312.htm auph-2022q3exx321.htm auph-2022q3exx322.htm exhibit1024separationagree.htm exhibit1025separationagree.htm exhibit1026separationagree.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "auph-20220930.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 201, "dts": { "calculationLink": { "local": [ "auph-20220930_cal.xml" ] }, "definitionLink": { "local": [ "auph-20220930_def.xml" ] }, "inline": { "local": [ "auph-20220930.htm" ] }, "labelLink": { "local": [ "auph-20220930_lab.xml" ] }, "presentationLink": { "local": [ "auph-20220930_pre.xml" ] }, "schema": { "local": [ "auph-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 420, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 22, "keyStandard": 229, "memberCustom": 17, "memberStandard": 40, "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - COVER", "role": "http://www.auriniapharma.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Fair Value Measurements", "role": "http://www.auriniapharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments", "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments", "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Inventories, net", "role": "http://www.auriniapharma.com/role/Inventoriesnet", "shortName": "Inventories, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "auph:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Prepaid Expenses", "role": "http://www.auriniapharma.com/role/PrepaidExpenses", "shortName": "Prepaid Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "auph:PrepaidExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Intangible Assets", "role": "http://www.auriniapharma.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Property and Equipment, net", "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Lease Obligations", "role": "http://www.auriniapharma.com/role/LeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Deferred Compensation and Other Non-current Liabilities", "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities", "shortName": "Deferred Compensation and Other Non-current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - License and Collaboration Agreement", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement", "shortName": "License and Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Net Loss per Common Share", "role": "http://www.auriniapharma.com/role/NetLossperCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Share-based Compensation", "role": "http://www.auriniapharma.com/role/SharebasedCompensation", "shortName": "Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Income Taxes", "role": "http://www.auriniapharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Related-Party Transactions", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Commitment and Contingencies", "role": "http://www.auriniapharma.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Subsequent Events", "role": "http://www.auriniapharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)", "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables", "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Inventories, net (Tables)", "role": "http://www.auriniapharma.com/role/InventoriesnetTables", "shortName": "Inventories, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Prepaid Expenses (Tables)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesTables", "shortName": "Prepaid Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Intangible Assets (Tables)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Property and Equipment, net (Tables)", "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Lease Obligations (Tables)", "role": "http://www.auriniapharma.com/role/LeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Share-based Compensation (Tables)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables", "shortName": "Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "auph:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)", "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails", "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)", "role": "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "shortName": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Inventories, net (Details)", "role": "http://www.auriniapharma.com/role/InventoriesnetDetails", "shortName": "Inventories, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "auph:PrepaidAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Prepaid Expenses (Details)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesDetails", "shortName": "Prepaid Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "auph:PrepaidAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Property and Equipment, net (Details)", "role": "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i0218c4022baf4887b278a279993662cb_D20210201-20210228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeasePrincipalPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Lease Obligations - Narrative (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "shortName": "Lease Obligations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i0218c4022baf4887b278a279993662cb_D20210201-20210228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeasePrincipalPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails", "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "iea170fa7b20a4b41b108e493dc1948f2_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)", "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails", "shortName": "Deferred Compensation and Other Non-current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - License and Collaboration Agreement (Details)", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "shortName": "License and Collaboration Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ibf32de36976c4acea4a8d8fcae729345_D20201217-20201217", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails", "shortName": "Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Share-based Compensation - Narrative (Details)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "shortName": "Share-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails", "shortName": "Share-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ib46a6c6687af4fd9a8a0a685adc3371b_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i2b58579e74a9437291aa1de82c974264_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "shortName": "Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i2b58579e74a9437291aa1de82c974264_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ic7fef15dae2646efa24f1995243223c6_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i4cb855b7f6c747c0a023b4b6dfc69145_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Income Taxes (Details)", "role": "http://www.auriniapharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ied2bf63884594bf3a519994bdc8a9be1_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ied2bf63884594bf3a519994bdc8a9be1_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i600c866525944e51adcfcdad3efc98eb_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "i600c866525944e51adcfcdad3efc98eb_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Subsequent Events (Details)", "role": "http://www.auriniapharma.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "ie1901be7a6424fe8a7f80634ccb66032_D20220930-20220930", "decimals": "INF", "lang": "en-US", "name": "auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Organization and Description of Business", "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20220930.htm", "contextRef": "if5bd943c4ac64248977ce4014afc6830_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "auph_AccountsReceivableCreditTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Credit Term", "label": "Accounts Receivable, Credit Term", "terseLabel": "Receivable standard credit terms (in days)" } } }, "localname": "AccountsReceivableCreditTerm", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "auph_AccruedResearchCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research, Current", "label": "Accrued Research, Current", "terseLabel": "Accrued R&D projects" } } }, "localname": "AccruedResearchCurrent", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_AcquiredUpfrontLicensePayment": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquired Upfront License Payment", "label": "Acquired Upfront License Payment", "terseLabel": "Upfront license and milestone expense" } } }, "localname": "AcquiredUpfrontLicensePayment", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "auph_AmendedAndRestatedEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Equity Incentive Plan", "label": "Amended and Restated Equity Incentive Plan [Member]", "terseLabel": "Amended and Restated Equity Incentive Plan" } } }, "localname": "AmendedAndRestatedEquityIncentivePlanMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_CashCashEquivalentsAndDebtSecuritiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents and Debt Securities, Current", "label": "Cash, Cash Equivalents and Debt Securities, Current", "terseLabel": "Cash and cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndDebtSecuritiesCurrent", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "auph_CashCashEquivalentsAndRestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents And Restricted Cash Member", "label": "Cash, Cash Equivalents And Restricted Cash [Member]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsAndRestrictedCashMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents and Short Term Investments", "terseLabel": "Total cash, cash equivalents, restricted cash and short-term investments", "totalLabel": "Total cash, cash equivalents, restricted cash and short-term investments" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "auph_CommercialRelatedAccrualsCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commercial Related Accruals, Current", "label": "Commercial Related Accruals, Current", "terseLabel": "Commercial accruals" } } }, "localname": "CommercialRelatedAccrualsCurrent", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_ILJINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ILJIN", "label": "ILJIN [Member]", "terseLabel": "ILJIN" } } }, "localname": "ILJINMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid", "terseLabel": "Future value of minimum lease payments of leases not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease", "terseLabel": "Expected payments prior to commencement of lease" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "auph_LesseeOperatingLeaseLeaseTerminationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Termination Term", "label": "Lessee, Operating Lease, Lease Termination Term", "terseLabel": "Lease termination option term" } } }, "localname": "LesseeOperatingLeaseLeaseTerminationTerm", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_LesseeOperatingLeaseNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number of Extension Options", "label": "Lessee, Operating Lease, Number of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LesseeOperatingLeaseNumberOfExtensionOptions", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "auph_MilestoneAchievementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Achievement", "label": "Milestone Achievement [Member]", "terseLabel": "Milestone Achievement" } } }, "localname": "MilestoneAchievementMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "auph_MilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment [Member]", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePaymentMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_NewEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Employees", "label": "New Employees [Member]", "terseLabel": "New Employees" } } }, "localname": "NewEmployeesMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "auph_OtuskaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Otuska Pharmaceutical Co., Ltd.", "label": "Otuska Pharmaceutical Co., Ltd. [Member]", "terseLabel": "Otuska" } } }, "localname": "OtuskaPharmaceuticalCoLtdMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "auph_OutsideUnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outside United States", "label": "Outside United States [Member]", "terseLabel": "Outside United States" } } }, "localname": "OutsideUnitedStatesMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "auph_PerformanceShareSandRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Share sand Restricted Stock Units (RSUs)", "label": "Performance Share sand Restricted Stock Units (RSUs) [Member]", "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)" } } }, "localname": "PerformanceShareSandRestrictedStockUnitsRSUsMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_PrepaidAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Assets, Current", "label": "Prepaid Assets, Current", "terseLabel": "Prepaid assets" } } }, "localname": "PrepaidAssetsCurrent", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "auph_PrepaidExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses", "label": "Prepaid Expenses [Text Block]", "terseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpensesTextBlock", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpenses" ], "xbrltype": "textBlockItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "terseLabel": "Potential regulatory milestone revenue" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "verboseLabel": "Tiered royalty percentages on future sales" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "percentItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform, Milestone Payments", "label": "Research And Development Arrangement, Contract To Perform, Milestone Payments", "terseLabel": "Triggered milestone, payments" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformMilestonePayments", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "auph_RiptideBioscienceIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Riptide Bioscience, Inc.", "label": "Riptide Bioscience, Inc. [Member]", "terseLabel": "Riptide Bioscience, Inc." } } }, "localname": "RiptideBioscienceIncMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "auph_RockvilleMarylandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockville, Maryland", "label": "Rockville, Maryland [Member]", "terseLabel": "Rockville, Maryland" } } }, "localname": "RockvilleMarylandMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period", "terseLabel": "Offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "terseLabel": "Estimated forfeiture rate (as percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of New Employees", "terseLabel": "Number of new employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods", "terseLabel": "Number of purchase periods" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "terseLabel": "Purchase period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "auph_ShareBasedPaymentArrangementInducementOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Inducement Option", "label": "Share-Based Payment Arrangement, Inducement Option [Member]", "terseLabel": "Inducement Stock Option" } } }, "localname": "ShareBasedPaymentArrangementInducementOptionMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "auph_ShareBasedPaymentArrangementUnamortizedExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Unamortized Expense", "label": "Share-Based Payment Arrangement, Unamortized Expense", "terseLabel": "Unamortized expense" } } }, "localname": "ShareBasedPaymentArrangementUnamortizedExpense", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "auph_ShortTermCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-Term Corporate Debt Securities", "label": "Short-Term Corporate Debt Securities [Member]", "terseLabel": "Corporate bond" } } }, "localname": "ShortTermCorporateDebtSecuritiesMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "auph_SpecialtyPharmacyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmacy One", "label": "Specialty Pharmacy One [Member]", "terseLabel": "Specialty Pharmacy One" } } }, "localname": "SpecialtyPharmacyOneMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "auph_USAgencySecurityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Agency Security", "label": "U.S. Agency Security [Member]", "terseLabel": "U.S. agency security" } } }, "localname": "USAgencySecurityMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "auph_VictoriaBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Victoria, British Columbia", "label": "Victoria, British Columbia [Member]", "terseLabel": "Victoria, British Columbia" } } }, "localname": "VictoriaBritishColumbiaMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_YankeeBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yankee Bond", "label": "Yankee Bond [Member]", "terseLabel": "Yankee bond" } } }, "localname": "YankeeBondMember", "nsuri": "http://www.auriniapharma.com/20220930", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.auriniapharma.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r280", "r408", "r409", "r412", "r530" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Shareholder" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r45", "r47", "r96", "r97", "r237", "r244" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r148", "r266", "r270", "r505" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r217", "r218", "r219", "r220", "r236", "r243", "r282", "r283", "r427", "r428", "r429", "r430", "r431", "r432", "r451", "r502", "r506", "r531", "r532" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r217", "r218", "r219", "r220", "r236", "r243", "r282", "r283", "r427", "r428", "r429", "r430", "r431", "r432", "r451", "r502", "r506", "r531", "r532" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r148", "r266", "r270", "r505" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officer" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r145", "r218", "r219", "r266", "r268", "r453", "r501", "r503" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r145", "r218", "r219", "r266", "r268", "r453", "r501", "r503" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r236", "r243", "r272", "r282", "r283", "r317", "r318", "r319", "r427", "r428", "r429", "r430", "r431", "r432", "r451", "r502", "r506", "r531", "r532" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r236", "r243", "r272", "r282", "r283", "r317", "r318", "r319", "r427", "r428", "r429", "r430", "r431", "r432", "r451", "r502", "r506", "r531", "r532" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r46", "r47", "r96", "r97", "r237", "r244" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r146", "r147", "r266", "r269", "r504", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r146", "r147", "r266", "r269", "r504", "r515", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r149", "r411" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]", "terseLabel": "Deferred Compensation and Other Non-current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r208" ], "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r51", "r53", "r54", "r489", "r511", "r512" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r50", "r54", "r61", "r62", "r63", "r99", "r100", "r101", "r363", "r405", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashFlowElementsSummationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements, Summations [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "AdditionalCashFlowElementsSummationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r99", "r100", "r101", "r328", "r329", "r330", "r370" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r285", "r332", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Shared-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r25", "r154", "r179", "r181", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r82", "r198", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of property (in sqft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r92", "r134", "r137", "r143", "r177", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r360", "r364", "r380", "r415", "r417", "r471", "r487" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r35", "r92", "r177", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r360", "r364", "r380", "r415", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r159", "r162", "r187", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available-for-sale debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r87", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Lease Obligation Incurred", "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r10", "r84" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash, cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r85", "r470" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r79", "r84", "r89" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "terseLabel": "Cash, cash equivalents and restricted cash", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r79", "r381" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash transactions" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r475", "r493" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r216", "r221", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r99", "r100", "r370" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value ($ per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r17" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common shares - no par value, unlimited shares authorized, 142,110 and 141,600 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r57", "r59", "r60", "r68", "r479", "r497" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r199", "r201", "r352" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Internal-use software implementation costs" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r128", "r129", "r148", "r378", "r379", "r516" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r128", "r129", "r148", "r378", "r379", "r513", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r128", "r129", "r148", "r378", "r379", "r513", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r126", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Major Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r128", "r129", "r148", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r128", "r129", "r148", "r378", "r379", "r516" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bond" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r72", "r92", "r177", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r380" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r71" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost of sales and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r127", "r148" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on available-for-sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.", "label": "Debt Securities, Current", "terseLabel": "Short-term investments" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent": { "auth_ref": [ "r159", "r161", "r167", "r473" ], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": 1.0, "parentTag": "auph_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current", "terseLabel": "Total held to maturity securities at amortized cost" } } }, "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets, Current", "terseLabel": "Prepaid deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r82", "r206" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Derivative, average remaining maturity" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r287", "r288", "r323", "r324", "r326", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r95", "r226", "r228", "r229", "r233", "r234", "r235", "r409", "r474", "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r69", "r104", "r105", "r106", "r107", "r108", "r112", "r114", "r116", "r117", "r118", "r122", "r123", "r371", "r372", "r480", "r498" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic loss per share ($ per share)", "totalLabel": "Basic loss per share ($ per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r69", "r104", "r105", "r106", "r107", "r108", "r114", "r116", "r117", "r118", "r122", "r123", "r371", "r372", "r480", "r498" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per share ($ per share)", "totalLabel": "Diluted loss per share ($ per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r119", "r120", "r121", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r61", "r62", "r63", "r99", "r100", "r101", "r103", "r109", "r111", "r125", "r178", "r246", "r248", "r328", "r329", "r330", "r343", "r344", "r370", "r382", "r383", "r384", "r385", "r386", "r388", "r405", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r373", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r238", "r241", "r242", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r374", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r238", "r273", "r274", "r279", "r281", "r374", "r424" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r238", "r241", "r242", "r273", "r274", "r279", "r281", "r374", "r425" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r238", "r241", "r242", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r374", "r426" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r238", "r241", "r242", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "terseLabel": "Minimum finance lease liability payments due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r392", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Capital expenditure payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r168", "r172", "r174", "r175", "r176", "r180", "r183", "r184", "r185", "r186", "r188", "r189", "r190", "r191", "r240", "r245", "r369", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r13", "r202" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r199", "r200", "r202", "r204", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r202", "r455" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r202", "r454" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Acquired intellectual property and other intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r156", "r163", "r179", "r184" ], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "totalLabel": "Amortized Cost" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "auth_ref": [ "r165", "r170" ], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain", "terseLabel": "Unrealized Gains" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "auth_ref": [ "r166", "r171" ], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss", "negatedTerseLabel": "Unrealized Losses" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "auth_ref": [ "r164", "r169", "r473" ], "calculation": { "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Fair Value", "terseLabel": "Estimated Fair Value" } } }, "localname": "HeldToMaturitySecuritiesFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r65", "r134", "r136", "r139", "r142", "r144", "r468", "r476", "r481", "r499" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r210", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r93", "r340", "r341", "r342", "r345", "r347", "r349", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r110", "r111", "r133", "r339", "r346", "r348", "r500" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r81", "r397" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Acquired intellectual property and reacquired rights" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r18" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Capitalized under inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories, net" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/Inventoriesnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods inventories" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r26", "r193" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r32", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/InventoriesnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r193" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r27", "r193" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesnetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r192" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r173", "r469", "r483", "r514", "r546" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Short-Term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r402" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: lease imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease Obligations" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r92", "r138", "r177", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r361", "r364", "r365", "r380", "r415", "r416" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r92", "r177", "r380", "r417", "r472", "r491" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r40", "r92", "r177", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r361", "r364", "r365", "r380", "r415", "r416", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement Terms" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License and collaboration revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r79", "r80", "r83" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r55", "r58", "r63", "r66", "r83", "r92", "r102", "r104", "r105", "r106", "r107", "r110", "r111", "r115", "r134", "r136", "r139", "r142", "r144", "r177", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r372", "r380", "r477", "r495" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r136", "r139", "r142", "r144" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r396", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r391" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r391" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r391" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r390" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r400", "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases", "verboseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r399", "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r34", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r358", "r359", "r362" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax of nil" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r48", "r49", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "terseLabel": "Unrealized gain on available-for-sale securities, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r59", "r61", "r62", "r64", "r67", "r246", "r382", "r387", "r388", "r478", "r496" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r39", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Deferred compensation and other non-current liabilities", "verboseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "terseLabel": "Payments for capital improvements" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r74", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "negatedTerseLabel": "Proceeds from tenant improvements" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r75" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Additions to internal use-software implementation costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLeaseReceivables": { "auth_ref": [ "r76" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.", "label": "Payments to Acquire Lease Receivables", "negatedTerseLabel": "Upfront lease payment" } } }, "localname": "PaymentsToAcquireLeaseReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r160" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r76" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Upfront license payment" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Purchase of non-current assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r75", "r355", "r356", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Upfront license fee" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Unvested performance awards" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r33", "r196", "r197" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r6", "r195", "r197" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Cash received for interest" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r77", "r327" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and employee share purchase plan" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r77" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue, net", "verboseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r211", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r207" ], "calculation": { "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r209", "r417", "r484", "r492" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r280", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r408", "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r280", "r408", "r409", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r280", "r408", "r412", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r406", "r407", "r409", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r336", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Upfront payments received" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r335", "r452", "r533" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r10", "r89", "r470", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r10", "r84", "r89", "r470", "r488" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted units", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r248", "r417", "r490", "r510", "r512" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r99", "r100", "r101", "r103", "r109", "r111", "r178", "r328", "r329", "r330", "r343", "r344", "r370", "r507", "r509" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r131", "r132", "r135", "r140", "r141", "r145", "r146", "r148", "r265", "r266", "r453" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Total revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r91", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Product Revenues" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r267", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r398", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Initial recognition of operating lease right-of-use asset" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r128", "r148" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Allocation of Share-Based Payments" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Loss Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r199", "r201", "r454" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories, net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/InventoriesnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/PropertyandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r284", "r286", "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r293", "r308", "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service Revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Performance shares forfeited (in shares)", "terseLabel": "Shares forfeited/canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Performance share forfeited, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, weighted average exercise price (in usd per share)", "verboseLabel": "Performance shares awards, weighted average grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding - End of Period (in shares)", "periodStartLabel": "Outstanding - Beginning of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)", "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average exercise price $" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Performance shares vested (in shares)", "terseLabel": "Performance shares vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Performance shares vested, Weighted average grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Annualized volatility(as percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Number of shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Fair value per common share option (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "terseLabel": "Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price $" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r312", "r313", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails", "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r291", "r314", "r315", "r316", "r317", "r320", "r331", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of Performance Shares Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r90", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r61", "r62", "r63", "r99", "r100", "r101", "r103", "r109", "r111", "r125", "r178", "r246", "r248", "r328", "r329", "r330", "r343", "r344", "r370", "r382", "r383", "r384", "r385", "r386", "r388", "r405", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r125", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r239", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r17", "r246", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common shares in conjunction with ESPP program (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r246", "r248", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r16", "r17", "r246", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares in conjunction with ESPP program" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r246", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards and restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r92", "r157", "r177", "r380", "r417" ], "calculation": { "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "SHAREHOLDER\u2019S EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r389", "r419" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r418", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r150", "r151", "r152", "r153", "r155", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r168", "r172", "r174", "r175", "r176", "r240", "r245", "r369", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "Treasury bill" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBondSecuritiesMember": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bond Securities [Member]", "terseLabel": "Treasury bond" } } }, "localname": "USTreasuryBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CashCashEquivalentsRestrictedCashandShortTermInvestmentsInvestmentsDetails", "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r113", "r118" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r112", "r118" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails": { "order": 3.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average common shares outstanding used in computation of basic loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.auriniapharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.auriniapharma.com/role/NetLossperCommonShareScheduleofEarningsPerShareBasicandDilutedDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r514": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r535": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r536": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r537": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r538": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r539": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r540": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r541": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r542": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r543": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r544": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r546": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r547": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" } }, "version": "2.1" } ZIP 84 0001628280-22-027931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-027931-xbrl.zip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end